-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IApn0dmzRqbSb1w/G0XtGEJmfBCfVM2Q2aevPzMUTeLYq/lTXtXihRGeFr0x/zo6
 opoZS5sZLhxM6L3vVbGnxA==

<SEC-DOCUMENT>0000950144-07-008048.txt : 20070821
<SEC-HEADER>0000950144-07-008048.hdr.sgml : 20070821
<ACCEPTANCE-DATETIME>20070821153043
ACCESSION NUMBER:		0000950144-07-008048
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070928
FILED AS OF DATE:		20070821
DATE AS OF CHANGE:		20070821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		071070681

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>g09121pre14a.htm
<DESCRIPTION>PRE 14A GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>PRE 14A GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>SCHEDULE 14A INFORMATION</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Filed by the Registrant <FONT face="Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Filed by a Party other than the Registrant <FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#254;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Preliminary Proxy Statement</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Definitive Proxy Statement</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Definitive Additional Materials</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting Material under Rule&nbsp;14a-12</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">Name of the Registrant as Specified In Its Charter</DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>

</DIV>
<DIV align="center" style="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Payment of Filing Fee (Check the appropriate box):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#254;</FONT> No fee required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(4) and 0-11.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Title of each class of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Aggregate number of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule
0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined):</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Proposed maximum aggregate value of transaction:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total fee paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Fee paid previously with preliminary materials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify
the filing for which the offsetting fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date of its filing.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amount Previously Paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Form, Schedule or Registration Statement No.:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Filing Party:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Date Filed:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
1256 Briarcliff Road<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>TABLE OF CONTENTS</B></U>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">Notice of Special Meeting of Stockholders and Proxy Statement</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">Proxy Statement for The Special Meeting of Stockholders</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">About the Proxy Statement</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">Proposal &#150; Amendment to Articles of Incorporation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">Voting Securities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">Security Ownership of Principal Shareholders, Directors and Officers</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">Absence of Appraisal Rights</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#108">Other Matters</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
1256 Briarcliff Road<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306</B>
</DIV>

<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS<BR>
AND<BR>
PROXY STATEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To Our Shareholders:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A Special Meeting of Stockholders of GeoVax Labs, Inc. will be held on Friday, September&nbsp;28,
2007, at 10:00&nbsp;A.M. (Eastern Time), at the offices of the Company, 1256 Briarcliff Road, Emtech Bio
Suite&nbsp;500, Atlanta, Georgia to:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">1. Approve an amendment to our Articles of Incorporation in order to increase the
number of shares of common stock, par value $0.001 per share, that we are authorized to
issue from 850,000,000 to 900,000,000 shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">2. Act on any other business that properly comes before the special meeting or any
adjournment or postponement of the special meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders of record at the close of business on August&nbsp;9, 2007 will be entitled to notice
of the Special Meeting and any continuation or adjournment thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Please return the enclosed proxy as promptly as possible, whether or not you plan to attend
the Special Meeting. </B>Your promptness in returning the proxy will assist us in ensuring that a
quorum is present or represented. Even though you return your proxy, you may nevertheless attend
the Special Meeting and vote your shares in person if you wish. If you want to revoke your proxy
at a later time for any reason, you may do so in the manner described in the attached Proxy
Statement. This Proxy Statement is being sent to you on or about September&nbsp;7, 2007.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By Order of the Board of Directors,
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Mark W. Reynolds</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mark W. Reynolds<BR>
Corporate Secretary</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">September&nbsp;7, 2007<BR>
Atlanta, Georgia

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
1256 Briarcliff Road<BR>
Atlanta, Georgia 30306</B>
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROXY STATEMENT<BR>
For The<BR>
SPECIAL MEETING OF STOCKHOLDERS<BR>
To Be Held September&nbsp;28, 2007</B>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ABOUT THE PROXY STATEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Proxy Statement is furnished in connection with the solicitation of your proxy by the
Board of Directors of GeoVax Labs, Inc., an Illinois corporation, for use at our Special Meeting of
Stockholders to be held at the offices of the Company, 1256 Briarcliff Road, Emtech Bio Suite&nbsp;500,
Atlanta, Georgia on Friday, September&nbsp;28, 2007, at 10:00&nbsp;A.M. local time and at any meeting
following adjournment thereof. The Notice of Special Meeting, this Proxy Statement and the
accompanying proxy card are being sent to you on or about September&nbsp;7, 2007.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Revocability of Proxy and Voting of Shares</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you give us a proxy you will have the power to revoke it at any time before it is
exercised. The proxy may be revoked before it is exercised by sending a written revocation or a
duly executed proxy bearing a later date to us at our principal executive offices located at 1256
Briarcliff Road, Emtech Bio, Suite&nbsp;500, Atlanta, Georgia 30306. The proxy may also be revoked by
attending the meeting and voting in person.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When the proxy is properly executed, dated and returned, the shares it represents will be
voted in accordance with any directions noted on it. <B>If no instructions are indicated, the proxy
will be voted FOR the approval of the amendment to our Articles of Incorporation to increase the
number of authorized shares of our common stock. </B>We currently know of no other matters to be
considered at the Special Meeting of Stockholders. <B>If, however, any other matters come before the
Special Meeting of Stockholders, or any adjournment or adjournments thereof, the persons named in
the proxy will vote the proxy in accordance with their best judgment on any such matter.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Record Date, Voting Rights and Outstanding Shares</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has fixed August&nbsp;9, 2007 as the record date (the &#147;Record Date&#148;) for
determining holders of our common stock, $0.001 par value per share, who are entitled to vote at
the meeting. As of the Record Date, we had 712,834,703 shares of common stock outstanding and
entitled to vote. Each share of common stock entitles the record holder to one vote on the
proposal to be voted upon at the meeting. A majority of the shares of common stock issued and
outstanding and entitled to vote at the meeting will constitute a quorum at the meeting. If a
quorum exists, action on the proposal is approved if two-thirds of the votes in attendance at the
meeting are cast in favor of the action. <B>Unless otherwise marked or indicated on the proxy, your
shares will be voted &#147;FOR&#148; the approval of the amendment to our Articles of Incorporation to
increase the number of authorized shares of our common stock.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Solicitation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all costs associated with the distribution of this Proxy Statement, including the
costs of printing and mailing. We will reimburse brokerage firms and other custodians, nominees
and fiduciaries for reasonable expenses incurred by them in sending this Proxy Statement to the
beneficial owners of our common stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Approval of proposal</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As noted above, each share of common stock is entitled to one vote. If a quorum exists, the
proposal must receive the vote of two-thirds of the issued and outstanding shares of common stock
in attendance at the meeting in order to pass.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROPOSAL<BR>
AMENDMENT TO ARTICLES OF INCORPORATION<BR>
TO INCREASE AUTHORIZED SHARES OF COMMON STOCK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Articles of Incorporation, as amended, provide that the total number of shares of capital
stock that we are authorized to issue is 860,000,000, consisting of 850,000,000 shares of common
stock and 10,000,000 shares of preferred stock. On July&nbsp;25, 2007, subject to approval by our
stockholders, our board of directors approved an amendment to our Articles of Incorporation to
increase the number of shares of common stock that we are authorized to issue to from 850,000,000
to 900,000,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Reasons for Amendment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We must increase the number of authorized shares of our common stock in order to have a
sufficient number of authorized shares to issue in connection with a subscription agreement we
entered into on July&nbsp;30, 2007 with PURE Capital, LLC (the &#147;Investor&#148;). Pursuant to the agreement,
in exchange for an aggregate purchase price of $7,500,000, we agreed to sell to the Investor in two
closings an aggregate of 48,387,097 shares of our common stock and warrants to purchase an
aggregate of 35,000,000 shares of our common stock, exercisable within a 3&nbsp;year period. At the
first closing (&#147;First Closing&#148;), which is expected to occur during August&nbsp;2007, in exchange for
$3,500,000 the Investor will acquire 22,580,645 shares of our common stock and a warrant to
purchase 18,333,333 shares of our common stock at an exercise price of $0.33 per share. At the
second closing (&#147;Second Closing&#148;), which is expected to occur in November&nbsp;2007, in exchange for
$4,000,000 the Investor will acquire 25,806,452 shares of our common stock and a warrant to
purchase 16,666,667 shares of our common stock at an exercise price which shall be equal to the
closing market price on the day prior to the Second Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of August&nbsp;17, 2007, of the 850,000,000 shares of our common stock authorized by our
articles of incorporation, 712,834,703 shares were issued and outstanding and 73,771,605 shares
were reserved for issuance in connection with outstanding stock purchase warrants, and in
accordance with our 2006 Equity Incentive Plan, including potential exercise of stock options under
such plan. Upon completion of the First and Second Closings, 761,221,800 shares of our common
stock will have been issued and outstanding and 108,771,605 shares shall have been reserved for
issuance in connection with our 2006 Equity Incentive Plan and potential exercise of all warrants
presently under consideration, thus potentially, exceeding our current number of 850,000,000
authorized shares of common stock. After the proposed increase in the number of authorized shares
of our common stock to 900,000,000 and completion of the Second Closing, 30,006,595 shares of our
common stock would be authorized, but not issued or reserved for issuance under any present plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that our future growth may require the use of our common stock from time to time
either as part of a financing for us either through the use of our common stock or securities
convertible into our common stock. Such shares may be issued in conjunction with both public
offerings and private placements of shares of our common stock. Our stockholders do not have any
preemptive rights to purchase additional shares of our common stock. Other than the Second
Closing, we do not have any current plans, proposals or understandings that would require the use
of the additional authorized shares of our common stock to be issued.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Effects of the Amendment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders should consider the following factors which may affect them, as well as the other
information contained in this proxy statement, in evaluating the proposal to approve the amendment
to our articles of incorporation to increase our authorized shares of common stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Possible Dilution from Future Issuance of Additional Shares</I>. We are seeking to amend our
articles of incorporation to increase the number of authorized shares of our common stock from
850,000,000 to 900,000,000 shares, and the interests of the holders of our common stock could be
diluted as a result. Any future issuance of additional authorized shares of our common stock could
dilute future earnings per share, book value per share and voting power of existing stockholders.
Depending upon the circumstances under which such shares are issued, such

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">issuances may reduce stockholders equity per share and may reduce the percentage ownership of
common stock of existing stockholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Form of Amendment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Amendment is approved, the text of the first paragraph of Article&nbsp;IV of our Articles of
Incorporation would read in its entirety as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;The total number of shares of all classes of stock which the Corporation shall
have the authority to issue is 910,000,000 shares, which are divided into two
classes consisting of: (a)&nbsp;900,000,000 shares of Common Stock, par value $0.001 per
share, and (b)&nbsp;10,000,000 shares of Preferred Stock, par value $0.01 per share.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Approval Required</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock is entitled to one vote. A majority of the shares of common stock
issued and outstanding and entitled to vote at the meeting will constitute a quorum for
consideration of the proposal at the meeting. If a quorum exists, action on the proposal is
approved if two-thirds of the votes in attendance at the meeting are cast in favor of the proposal.
Abstentions and broker non-votes are counted in determining whether a quorum of shares of our
common stock is present at the special meeting. A &#147;broker non-vote&#148; occurs if a broker or other
nominee who holds shares in &#147;street&#148; name for customers who are beneficial owners of those shares
does not have discretionary authority with respect to the voting of the shares and has not received
instructions with respect the proposal from the customer. Neither broker &#147;non-votes&#148; nor
abstentions are included in the tabulation of the voting results on the proposal and, therefore,
they do not have the effect of votes in opposition in such tabulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Effective Date</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Amendment to our Articles of Incorporation will become effective upon filing such
Amendment with the Illinois Secretary of State.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Recommendation of our Board of Directors</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Our board of directors has unanimously approved the amendment to our articles of incorporation
to increase the number of authorized shares of our common stock from 850,000,000 to 900,000,000,
has determined that this amendment to our articles of incorporation is advisable and in the best
interest of our stockholders and recommends that our stockholders vote FOR its approval.</B>
</DIV>

<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VOTING SECURITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of August&nbsp;9, 2007, the Record Date, our authorized capitalization consisted of 850,000,000
shares of common stock, par value $.001 per share, and 10,000,000 shares of preferred stock, par
value $.01 per share. At the Record Date, we had 712,834,703 shares of common stock issued and
outstanding, 51,000,000 shares reserved for issuance pursuant to our 2006 Equity Incentive Plan, of
which options to purchase 38,127,757shares have been granted, and 22,771,605 shares reserved for
issuance pursuant to our common stock purchase warrants. No shares of preferred stock are issued
and outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock entitles its holder to one vote on each matter submitted to the
stockholders for a vote.
</DIV>

<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECURITY OWNERSHIP OF PRINCIPAL SHAREHOLDERS, DIRECTORS AND OFFICERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based solely upon information made available to us, the following table sets forth information
with respect to the beneficial ownership of our common stock as of August&nbsp;9, 2007 by (1)&nbsp;each
person who is known by us to beneficially own more than five percent of the common stock; (2)&nbsp;each
director and nominee for director; (3)&nbsp;each of the named executive officers listed in the Summary
Compensation Table below under the caption &#147;Compensation of

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Directors and Executive Officers&#148;; and (4)&nbsp;all executive officers and directors as a group. Except
as otherwise indicated, the holders listed below have sole voting and investment power with respect
to all shares of common stock beneficially owned by them.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Number of Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Beneficially</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Name and Address of Beneficial Owner (1)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Owned</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Percentage</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Directors and Named Executive Officers:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Donald G. Hildebrand (3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76,972,107</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">10.2</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Andrew J. Kandalepas (4)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,890,065</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.0</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Robert T. McNally</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">617,742</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Dean G. Kollintzas (5)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">440,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Mark W. Reynolds (6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">600,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Jack N. Spencer (7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">440,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">*</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">All executive officers and directors as a group (6 persons) (8)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100,959,914</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">13.4</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>5% Stockholders:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Emory University<br>
Administration Building 101<br>
201 Dowman Drive<br>
Atlanta, Georgia 30322</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">233,905,253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">31.8</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Harriet L. Robinson (9)<br>
c/o GeoVax Labs, Inc.<br>
1256 Briarcliff Road, Suite&nbsp;500<br>
Atlanta, Georgia 30306</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69,321,865</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">9.3</TD>
    <TD nowrap>%</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Less than 1%</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Except as otherwise indicated, the business address of each director and executive officer
listed is c/o GeoVax Labs, Inc., 1256 Briarcliff Road, Suite&nbsp;500, Atlanta, Georgia 30306.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>This table is based upon information supplied by officers and directors, and with respect to
principal shareholders, Schedules 13D and 13G filed with the SEC. Beneficial ownership is
determined in accordance with the rules of the Securities and Exchange Commission. Applicable
percentage ownership is based on 712,834,703 shares of common stock outstanding as of August
17, 2007. In computing the number of shares beneficially owned by a person and the percentage
ownership of that person, shares of common stock subject to options currently exercisable, or
exercisable within 60&nbsp;days of August&nbsp;17, 2007, are deemed outstanding.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 59,180,847 shares of common stock and options to purchase 17,791,260 shares of
common stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 21,290,065 shares of common stock and options to purchase 600,000 shares of common
stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 440,000 shares of common stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(6)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 600,000 shares of common stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(7)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 440,000 shares of common stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(8)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 81,088,654 shares of common stock and options to purchase 19,871,260 shares of
common stock exercisable within 60&nbsp;days of August&nbsp;9, 2007.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(9)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes 60,426,235 shares of common stock and options to purchase 8,895,630 shares of common
stock exercisable within 60&nbsp;days of August&nbsp;9, 2007. The stock options held by Dr.&nbsp;Robinson
are pursuant to her service as Chairman of our Scientific Advisory Board.</TD>
</TR>

</TABLE>


<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ABSENCE OF APPRAISAL RIGHTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated in the State of Illinois and, accordingly, are subject to the Illinois
General Corporation Act. Under the Illinois General Corporation Act, our stockholders are not
entitled to appraisal rights with respect to the proposal to be acted upon at the special meeting.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OTHER MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Shareholder Proposals</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any proposal which a stockholder intends to present in accordance with Rule&nbsp;14a-8 of the
Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) at our next Annual Meeting of Stockholders to
be held in 2008 must be received by us on or before January&nbsp;10, 2008. Notice of stockholder
proposals submitted outside of Rule&nbsp;14a-8 of the Exchange Act will be considered untimely if
received by us after January&nbsp;10, 2008. Only proper proposals under Rule&nbsp;14a-8 of the Exchange Act
which are timely received will be included in the proxy statement and proxy in 2008. We reserve
the right to vote against, reject, rule out of order, or take other appropriate action with respect
to any proposal that does not comply with these requirements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of intention to present a proposal at the 2008 annual meeting should be addressed to
Corporate Secretary, GeoVax Labs, Inc., 1256 Briarcliff Road, Emtech Bio Suite&nbsp;500, Atlanta,
Georgia 20206.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Delivery of Documents to Stockholders Sharing an Address</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will only deliver one Proxy Statement to multiple stockholders sharing an address unless we
have received contrary instructions from one or more of the stockholders. We will promptly deliver
a separate copy of this Proxy Statement to a stockholder at a shared address to which a single copy
of the document was delivered upon oral or written request to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">GeoVax Labs, Inc.<BR>
Attn: Mark Reynolds<BR>
1256 Briarcliff Road<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
Telephone No.: 404-727-0971
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By Order of the Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Mark W. Reynolds</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mark W. Reynolds</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Secretary</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g09121g0912101.gif" alt="(PROXY CARD)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>PROXY
GEOVAX LABS, INC.
This proxy is solicited on behalf of the Board of Directors
for the Special Meeting on September&nbsp;28, 2007</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">This proxy will be voted as specified by the stockholder. If no specification is made, all
shares will be voted &#147;FOR&#148; the approval of the two proposals set forth in the proxy statement.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">The stockholder represented herein appoints Donald G. Hildebrand and Andrew Kandalepas, and
each of them, proxies with the power of substitution to vote all shares of Common Stock entitled to
be voted by said stockholder at the Speciall Meeting of Stockholders of GeoVax Labs, Inc. to be
held at the offices of the Company, located at 1256 Briarcliff Road, Emtech Bio Suite&nbsp;500, Atlanta,
Georgia, on September&nbsp;28, 2007 at 10:00&nbsp;A.M. (Eastern Time), and in any adjournment or postponement
thereof as specified in this proxy.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>PROPOSAL &#151; Amendment to Articles of Incorporation</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Amend the
GeoVax Labs, Inc.
Articles of
Incorporation to
increase the number
of shares of common
stock authorized for
issuance&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR <FONT style="font-family: Wingdings">&#111;</FONT> AGAINST <FONT style="font-family: Wingdings">&#111;</FONT> ABSTAIN <FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Please mark, date and sign your proxy card and mail it in the enclosed envelope as soon as
possible.In their discretion, proxies are entitled to vote upon such other matters as may properly come
before the meeting, or any adjournment thereof.</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>By: Date:</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#151;&#151;  &#151;</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>By: Date:</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#151;&#151;  &#151;</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Note: Please mark, date and sign this proxy card and return it in the enclosed envelope. Please
sign with full corporate name by a duly authorized officer and affix corporate seal.</TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g09121g0912101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g09121g0912101.gif
M1TE&.#EAE`(7`L00`,#`P("`@$!`0/#P\.#@X-#0T)"0D*"@H'!P<+"PL&!@
M8%!04"`@(#`P,!`0$````/___P``````````````````````````````````
M`````````````````````````"'Y!`$``!``+`````"4`A<"``7_("2.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__P*!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZ
MO^"P>&P:`,[G@0B-5I<*@4!B1&!#"N<"/B_:D_^`@8*#A(5(`P\/!@$/""(-
M#PH`C(XB!`(-:@H,`"(*B02/`2("#PPD`@6&JZRMKJ^P7(F=D`<0I:,0M8\/
MH2(,#J$##`\+$`25Q[-]!K'.S]#1TM,LRZ7-N*0/HP>F))\*:XD'X20(#PV>
MU.OL[>[OL@\``P[!M]L0]/8+#P(DC`Y&G.M5@MZ#`P94P5O(L*'#AS<2*5@0
MP%<I`0L<-+#8[U^B$<.*F6#$H!G$DRA3_ZI\MPS5M@0/'"@\YV\$HW0B#@1P
MH,A$RY5`@PH=^N>GME&?<!+X.**4K3OA#,14.,(HT:M8LVI58C7;`$B5I)HL
M(#)?S7LXJ\K;RK:MV[<S!B00(,"`+P@`%@A`H*H`W4YX%R`((.`I@8F=!B"@
M:Y+`W+I4X4J>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P,P\P
MH"``@@,)"LB-P[LBG<$(#+B9%."`L`0!`%M2#D%G`+L#=!YP<V>1'!1U2!2P
M'F>.",7=F8-$7GQ['#?(O>>C_1R`^MCPXW\IP"!3SK40E@U8`%CJ4P4.``86
M*B4$4,YWQ!B#U_]9-G6$@H$%=G33(][5EL(R2T4RPH$).%#.5[G()^*(5H1T
M%P3)B8!A=@"@`U),:G1SB@@),&?0B2T^,`<"U#7((`DW>E13(GKTM-Z%^)5B
M9"X$.,``=;.1*.643T@U(TB^S#)`B/PDHXN1/#T58DZ0C`G!.0[P=0(C/XYP
M0)E"*N/``!DJ(`R2@#U')(J>:`@DE8`&:@0_;:JE0`,A)C+F12*P><=3-G43
M$)`)/NC@2))ZQ``"]?DRD`,FH=`24C#FPI.9@J:JJ@^,YL.&&K,LHM:B#F8(
M1PEG0$`,I/<=M.:E).2ZJX\06*E0`L3@(RI^HWR%3BZ*KBKMM#I(E1;_(CJJ
MN)8MJG1)`B2A?E)7"10%`$E:4$EE3X0,*E3NN<1^J8!"6\:$9Z.6\%33@-3V
MZR\,06H+F'Y\MG@MC".0-2<)!#QE$&`#**!&*>@V>BD!HS3\'4]Y.EB*).$&
M5`"O`N,K3DTREA#*`>+]ZS*U!3B@8'[X)3*'8N7XYTF`)0A@)H/B>N)=AF9.
M>$P#M@#MX(0RUB&3"!1!$&8)^GEIP%GGY*(8`0J_[+6_L]56V\WD]:8<,K8)
M9T(".,JA!@'6`2!=*,3YQDQO<=3A]C%QF\<;8`4D8``""'AW=8B[E:=39+P"
M@$!M=GD2ZM>45^Z,<99GKCE0[FWN^>>@AR[Z_^BDEV[ZZ:A/.T!D3*R^0\O?
ML0X(`">B8$:/?]SN`NRI"QH)(Y$@$"`C9O(C>Q+&UT!\L4:2^X!"QS/,#^\M
M$$#,"M8_@/WUCWSRG@E-`GBB*OOAASWPA#&`J@SUKJ^RA_;()=%B`;@A%@W1
M]UY:)<O4V**9!U@`[I00P`&^X']W2,4)"GB,F:6`$=1K02E8,,$55+`;R#'@
MAIXW.>18+(+!8@HQOC<#!*[@$]LAP3(,I@:_Y&\%%=/?:;*$GSIL8Q)ORQ5>
MDA.9,S@F`.1+`P!,,HFG[&$/9DA#'>Y2!\!,`@"1F0UNOK,(7_POB<.Y3A/S
MT8`&S.,8Q0&)`71B/O]+/&<XM,-ASWHQ1A+HA".S40\<[#;!B#7/32DZVO.T
MXZ%.0!`A8E1;"+5W#R*&\3O264XGIM@<`\#$3+.Q&P$@P;J6E`F+6!SB&O*X
MPPK)0QA5[`,49Z,*A-!.AIKY28OV(C->X"4=LAH!3!B0@$^$XAR;T)ZYSN2/
M&R&@$U*IB0._],IB+8IMZ:!'`A#1"02>8Y$"6,HH(-$<4U2$/@/8RR,6@*PR
MMD@N"X,)*X=YC0[5I#8`L$<I$)"\`_@C(Q/3WB7\U!1'(`HOP]J@SU!4C',T
MXRN3J%B.("!.->QR,5R$HK+`X@!_<`H`V0")`Y:Y%@#D4RT=.\4SSQ2)Z[G_
M4YG-B>8-B9$<93(S'^C@1QQX)`E49D:5^*C@!)?''`0NQ1'$<QT^6E3*?D"*
M&#%:(S]'P1QTX(&?I#`&`B$HM6DZHH(.T@M26S0'IC9E2,U`8`6;0LAS<&TM
M,=4>`C/"STY4T*KB\..DMBJ.7#"U(U+!BS<5)0#UP8JHSR-+,SSVR5`T0JYC
M8D12M>$39GV$J3E5A0-&09>FZN*IA!3L+10$(]T(8**N<^EE8,I80DZP2?WH
MD0DEA!\$FI`8RB'>=(0*6@'T"$U)\ZQ8\0%!$Q(V/T-2GP)2@=@R.J@C6B4D
M5S_(B-IH<X((7%T`4'N/#WK$CVMA*V"=VQ%<+*9Q_TPI!7]VB@\\$.JVT[5M
M<\<K79IEM*SHE:O/]")>F<I616>!R5\UNUGS!?>V,9MO6^&;7K+@U20T>1&H
M3%#!_'H)`I]X0/E($9"ERJ-%#H3JD-#56^8T5$5*#:M0^8FQ;`T7@?191'0C
M6T:I0%<5TC7A6_U1"@,.E)_/XVXS.(6(FFS5M,J"FF?7*ER,ZABG:[%JBY(!
M89?HF,'\=9/-Z&L9SI)7K`08A@.'K(QFH#5-!-UCPTJA'.\1&,I2=B/SMJ-@
M761X%$SEB2K,2LC0$F!Z>%E=3S8Z@@4DLR?W-3*"3T&6FLP!N?C@!WK/6D:R
M[(C'N-J&*E;,O&;5E"G\"/\'EF%2I%'PE02M?"0)I**&!BBHO,L@BWTJ/()Z
MJ&$.:L9+<\G<:<J>A5MW9+);Y+<-7S!B`?3Y)&H!X$4OAK`!".CB`,H7H@1X
M,6J\/@PZ?$$?\.VZU\RI2P`^+0<&A.+6;\:'I/B3/>@V([^%@5J:X$0'6A+&
M8KAF[E6KK9!/,$"`W;ZU'053:]02NT#\:<`<NMTS6A*[1=9V%K`9!CQV(NK4
MQ\Y83`[@)`+P6P1264PQ>N0S9(7BX?F0KV!\I@9BW_L^#>VIS#K1(8G=HMIT
M,X6M%8`L#<JZ,VKX8@CK%T$SU&Y-*H@Y[N@4F:.N0'<YEWD?'.[B%S+L&.+1
MPPK_G.ARE0F]!J=\@<WI</'\<8U.)_"Y#[(#DJ=KAWK#!N'+22->&K`3<V-/
MN]KYN8";Q\``$UV[W.=.][K;_>YXS[O>]\YW&#R1!EA\`7*FXW87I##K4/RZ
M#K^#AL*G8$M-Y\'@L3X$/!A]!<BA2G0X>0*XK=:,-;4;7E[5=U7]CR`OX)H(
MZ,P""TW2?1(LXXM^-!"J`(^$*?#.\HC@^GL*/B[`BL%`LC4,;!R8#CQQ43$'
MTRA[-C,1B9A4Z07%C\R^0``=$[LRA@9[%AS^!,$W$#V!I_T%?:=^1%@*]P]8
MJ!8$/_7-"";SJMKC34>9N??\YDEW::`X8&3Z@F)1OM(<_X23&%4T;2`!#K;`
M"+4D0'WP.#VW<);0''*P&*%B&R%B&SR",;FP'0I@<KA5(&119KG1$CCC'2>(
M%TX"1*&D$Y.@0'BA`(/!>6B#?AQ8`(+Q!A)X##3R.,.V"+6$?2JH/J&0`#ZX
M0P?@3G9R./!U..AQA"XX%VZG(9)2`+NU`HP09=R5`#`!7=:W`"0#@"0R27L$
M=W=`$&Q"5M_Q"0G!3RSW5TW2,`O#548E#IE@8F<2#NJ3AX@0#I^%67X2?H7$
M)Y9D'&N!-$NA4%Y4+\\G`,B2#DMA"PP032!1$A"P`.5P#0RX1G5(4*=PA<5U
MB7,B:O.`+`@V)#)14%Z5']9&%O_A8(I7:#`H5`;XD6#M9P[^@&-Q$&3F@PB1
M)X:Q44$-,"1`%H96Q6CG(%?OH1C0-P?)%0F(P%B9@`^WT5Q-0E%#\B/<H'*V
MT#]@53C?&(+H=5],Q59=R$_Q-%U`,GQS,(SHR%0PT8W[X@^,`"NY2%M@96,!
MX8[UV"(',A('<C7CD',,L&;<M8O0I1P!!(R!(F'\A58-DGTAB`MQ<#9]4`JG
M,%K8UP]_DV/CA2+?)8XV\0L39UYN&`=D5!MAM#05I6%4I0L,0FJ`-B;,AI&L
MR!L=]GR6EELX&8(.U@F79DUY4W9TX%KW`3?>D`+5>(;_A8>,0!5@R)"`4D&3
MJ"+A`)'_SH5>'<$/-[=X,XEAKI@PRG=;[OA;VF@Q_+,6.@-Q`YAD3)5G;[(8
MC,.+H?"5(^"5VN,DSR57>U43>JE"]XAF^4@*Z?"7^W4"#LAFKG0':T-$CL53
M9*%6*O2+4ND:%<0IVY=>FZ8C]`>4_M`-`K1X%N4&CR-7&2:)\A`EPQ);<L4C
M9ED@WX%Z&*)R#;,4UJ8Q&E$`.3E==;01G><`MG`HA"5>H[EZX?`)HR`<C&!E
M!)&;RI:<]CA=;X43BX5@^"`<1&F=B7`*6:@+X9`U?`1]ME":;_((P9D,"3!,
ME2D?;R:$$?,XS6*!9?"!PV:!$-5V',4`C4,X_!ESQ0`@E9!K_PY8`)`03>TY
M#PQ`2PU@;?=Y%SBH-K8@%XRQ,O50"0R'903EB(HQ+E?#%^PU@HE`B;)$$;C6
M0-C7H=3A./S)(V91A\4%($\Q%S=#,6N&$7"S%\@P+L!F()60376(HF]`%W3A
M"!MJ(&H`=PRR&$)*/L`!/<!!'0H0ANO)9-E)!OO!&WLH!%BY!5LRI5XZ<X5`
M&W56?LHC>UHP&Y3YI7W7H8X7!I%4D4.PH8+$!6VJIG9ZIWB:IWJZIWS:IW[Z
MIX`:J((ZJ(1:J(9ZJ(B:J(JZJ(S:J([ZJ)`:J9(ZJ91:J99ZJ9B:J9JZJ9S:
MJ9[ZJ:`:JJ*ZJ'O`!@ZG)B2`GU;@0?]2=`RHFA/=]P/(<'E`H*H$-8.X)T:-
M\X\'Q*NR^JHQR`(`P*O#RCZ-MP:TD:8^<!W(&J6QBIAUB@*VJ@.M6D+EH!,J
M4*Q'\&:PNAZ\,JM)@*V"P'*\)@EOY&N;IJQ($#BNFC'HF@_NU`.1-TEDV@."
MA!L@\D)HHQWUQP(MU*]29WCO>H;>5W]D`7Q#XP@*,#E(D!N6H+`LYP+4,:<P
M0+$YL*\S<+#1<8L$>P11LK'MRC`#FP--![*"H!#[Q)A"&`9Q0`HUQ;$S\*PK
MZP3\\0(MJT)^-S"`Q[`J,+,JXGX^00/X$4M10+0VBP4W.P.$!%$K`+!%P+0H
M\C/U*JP@!+7_A)"R+CM$Z.$+22@>;#,)OL`V!Z`*GI=#\X`'JY,&H]=U\X`&
M=S`/CM$HN>"S$!5'@=0C?F`&QP)$C;*(8`0I4N2S=W!(8!1U;L(RQ[!,;41%
M@A0=@L0VK]2&/C<;<XH0S(>S21ASN:*WY=:&VI.$=UL0CJ0;F`@XS$HC=-1,
MB?>Y@(L0=R%<&-,B>!2V#1,]:V&%+042M@"ZEC!&`S1$-[.[E2MZR,%LG8"[
MG1"WJ.L+<*,V+7)*D`NOD9.XL]$RT=NU;T`[*8(0;@`'O&*Y3$*X)X`<RK&T
M/Q)'"L&ZLI1'C@$WL,J\R8$CM(-$2Q0=:U`329NUT[M#-N)#;_LV_[Y[#"6A
M$&]TE\4!LV&`M;?`<C*(3WX49?]('X1S66:P*;5AA01E'YO0'!&:I9QW;B<%
M!QLJMRX;+`T@@]6)#,7R))4H)II@6=-A`(N8`+:P`,9P"7)64U<9#HI1+,Q1
M$1&S)<`F/!GC"`;P)/L!3A7<3`V0$#A8Q"L\,;J1I54Q&%49F5!#'03JN<FA
M;ZX:Q>:@7(?14H!4F@BF&]'5";E[0UZ<Q-:3OC02%80D,62!!Q;L/K?[@<S1
M#5T\!QAL;*)5PUD6!U6)8'*F"O/"3$\,%9(PPF?,3-E4P7*51IR0#_!6D(I1
M$ATB6I4,Q!&L%X(#*K7D",4*(;<PQ:-`P_^7J)Z-DC1/8;XEP".WDA]]C"*N
MK!B(D@ET_#P];`"/)@I04TWW2\*H0!$4C")3/#E'?'Y0D<&KT\2(?,AG4L,(
M#`8*+(10*X3C4CN.^`M)XQTU>PN5<,(A<@`SPJN^>`OQ%W/X.[<OFQ.?J))E
MA(!\XA?B8`8UH3[BAV!/X;-<:'[)QH--T0QT@Q/FC&#R[#@WX\XE'+4(C9#D
M0,Q580D$\8'Y<&`K&UE(D="8EKP.+355P85A49>9-]$.'4N[E!^_D"4A1<B,
ME:LJDB>HHM&7"!C:9!,2DR5OTPONY-)&"''7YE:YP+0_72P.!RT_6\(HG0[9
M+![:3-`%`BW-Y`___\RT$>W0^OP)#Q+426VU(L`S+.W0OM&RO)83/K-<77QQ
M)>#%",BN*FU^']T4@*&?UN-_#$(/JJ`VX7Q<T.32UC/,A7#-4UW",5/)J``8
MS)?1>5(3B4@"M.2^Y&(<&SS4[=S0@*W2@OLBM8DB9_%@0U("/',+XB$W"&6=
M+)HP3C+8*"7:A]TS-BW3K%UG0DTU<JT,T<$Z&4W"F7T?E$C6PG76/]-8)MVR
M*2N[*GVP/YN_L2TJL$W;#LTL=]T``_;6ND`<_U`TLVU^RNUY;5;;Q2U6-N;4
MQYO:41W3<$W:[S3;3EL"21@U;^W5U22B-,W!R%;9W]`(N".FPH,Q)@VU_\J]
MLA5YBZ4IU8W"8GXT)E=SV8,@V'#MGENR+@T=1BL+G(U2#L_!PF9]VFY4%\/`
M2/[-T'=Y%J<P+A/X#<\!<5?2"U"[1SQ(X<M-4$352Z_D)<.V$W4@XNI,!^[-
M@RL+X(P5*F]FX6;RV[X@-@2FLPY-X@+]'6^6#BU+%A:!$&=!T@.7U"V+B6LP
M(]H#Y<D],W490<PRTR3LXJ;\'<T1=T1.SWPSY1]]LTR;X);`K6_]VYV`Y?C4
MX.*=#P]^(C=;450=XY<HY/FA$(7W2Q\-RT#2Y%8^"H9.UOCKY3%7Y<A7(PN;
M*(#]WWG",M)7.]>H$&3NAW[DY<L,UU>[**HMA/]S&QG=?`L3L]A00W)U[B6;
M@@(#MEPA3LQTBS+)R3,6&S,HR#/VS+3[L1%1<H75C0IS\%&YDA?_0`IX@!,>
M!'?`%!U/4PD]#MO27BS4K@:7:]*7@'QAB'VP0L+93K&F$K43DPM/$HG-@6*T
MX^(TG4Y'BM2ZTBQ;CF=F!3$D%.9!*];"Q!QJ<^)EEDUGF%6TXRMCV^:4K0R[
M"P>.L!3CWNHJ..]X[MI\<LK7;=Y,V\T?Q7#</@IV%F7?1C)E5AOC3NHF,RDT
M7?(T5Q-Z-7K+KIXV+%>O>^E2^PAJX"%T$H925>"O+MIR9O"-/1>%D!>H^J!P
M@VL/JAB#P;`8,3A^O`#_@O0X;?1FH7`UZL%YW_`V/6H`N(8,",`U4@\E,@A(
MJ^<D4NI`?G$>^;`IP\8/#4`^=448($A0'G+$N4$186\.38]/*T6::+]ZIM`7
M8Y^>P@'VMQ3X9Y(F-AP9!F(`%.N`)2##7.B(B+_X^MDSMM%,EK@?@T'`]<`M
M8T\8E<\VA+,R4I\+,GH'DWC$W``,CK#T&0PD<V$75KCWLF3YIY^'B^LFM<$_
M*T7`L)\3H>^J87_[(E^B%VH+X0-WS=#XLA]`LC(;2C_V"3/VA'/BOQ'V$"4<
M7A\X=T]+B\].N%8^<;_XD<$I$QPX&OK]J+#Y&6KZ8:_^BS%$)=H<P__$N.]&
M_^`,`I"8",E@+`6!((0X+L%1B$7S+,/[)L>.*`P^B*&1@!P8#H3HX%`@C+LI
MM6J]8K/:+1<B`'2QBC"Y;#YG`0(T.SM@MN/R.9WZJ./S[(1+[_\#!@K2?;$-
M!`@-*LZI+6X5&"CT.5)65MU99IX5'&EZ?H)6`BP@Z)P1"`R%KAX6KB8L@*W.
MYAT(&-#FZN[R]OK^`@<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?6P\,X28$>'NK
M'G@;F!(8?)N(H-(LJ.Z\+?@:,&R=*`B8OA0H!%3/Y]G#MP5``UE44'0A:!`;
MPX8.S?1#TD=`1`)C!C084H`!#0@`,"E@H`,5O@4.IO_T:>0+4Q8#8%J\Z..M
MRZ1A+$\=?%FSRL2%[W9:Z;D+:$P_1!\BK>8@AP`!+BCJ@Z!@S(LD(CZ^>(`+
M`H$A$44,H*JRU\TKKO1%G/GHJTTV+JF<Q?+6BT\R!2+&9465RET]89,"QG8@
M7@&G7B)V?.".P`,P6+DJ%K'U0+X!"Q@$(*!F5$1M"`+DDQP`IK@""Q0,.'&`
M1#_5,T\@F!P`C#D"A[R9*@L!$H).`1@H4&4#*K@2ZB*Y&YY9AK8`-`X,$5=J
MQXJ[QE<`4'"$]Q'5K*N.-M7-`(W;H$5@NFN@TPL#!N!X!IW@B;O?P2'`WIK=
MM`'Z7KJE,(4X^`EA"WN[-0#_50D!!.A1)`M5%\!U"&1W1`+OE7<.`01D!@!S
M2+ASB'N686;;-P,H-T(`DC1GVA@2=@+`@QY),E5JEV46F(X,-35:/Q_Y],"/
MC=G"EA4J`<````,PX`)J7L#11#^##9```^LU@!H"J3AQP`H+>J$#$/@]()-4
M8`2!'DKQ0)"1"'FI)2$!&^%WD0,'J@7%;I@8X`*%$"300&59=E,F`0T@`!T!
M;&;T!I<.^/!GH`-PZ!&::&X%$H$['`!&1$\*P$1>=+TIYA@%*.:<*Z':\XXM
M7&TY)ST[J,5J)`YZY,`D&&D7@*&(0M<-5QSMY@````P1J@@YOD#5CVN<*14N
M<=(0_X"@5BX)G*RX`J`KJCZTXQ&T.Y);#53:>-38%$*F2U"46"`)[1<;>:.G
M/C08L(9*\T&@%@+QJ$5"#65*Q40"-)@05D1E?2;9K'"FM3`1%#%8'V+T#/#`
M$:VQ!.D.KC2`BRL-$T&/OSET/(/'.B3,CYH0.`!::$4LN1MF*XI:5R$"[^D"
M2ZLZ-NY5T*I55JU!0W":-P)T]*8L(9/:IBRG-1'S"]WJL)<("RQ@F[@CI.:R
M6C&/IJ^\$BLM(0V8S#16N6]#`Q5^Z"VF+E8%W*E%O$Z[/46!9F?5;T2-Q#FN
MNG@3`58`"9!<EMR/0;RLQ&I103E'[G7MPV.'?2S+3*L.?O^'6IO]/*4##;AP
M".,2VVSL%`C@\'7G<'EJ.!@_RU)(WRH5/<717X_JM.11J]OON`RP^6:G[N`G
M@%:RJ]YP[SNH)/<=>;']+-S;/R-WLUI;E:YD#H16Q=YTH6K*0C)\K1)&@H_`
MA%I.9&4*1<FZ,'VS;!(D/*T1JZD(5_O?"U8$F@?`@3$=,<X+1G8$5RB`?PV`
M'Z!:\(`%\J%.\3#,]%S0'^IP)63INTK49D<_].@`=\+;'=%85T"\((T48&E:
MU'H3M2LM"P[D80![DO0N=>2J`-7+7S_&%B/962]I\%G;\/K&O2<:PWM@<9/-
M.K*Y!0@*7H+2C+S`T``CK&8'"R#_QY:$*!(B^(!!6R/B"Z#&N*J<1`0.4`%%
MF$B=.4+`AB7,8;4D1H"E>*@FH^D(8YP4I7_A9X(?P\4`NJ@./-I0C4GS4SS>
M)Z,*PHR.SH$`)BJIR&71P(9?[,$##S8%D'$##C\SI>Z$)CO]\9%4C4B`D`#P
MPULTSW]6TH%AD)6K?"AK"J#2S!;GB`KG##*/D+H0$B5&R]FHLHE;+,`/H6C-
M7GB(/%00!R+*(8YTB.@H(N!'B^Y"&4=M11^A,HT00\:^?HUQ-EQQ3Q_>\,[V
M5.46"4!--PZTF]ATHAN4H<X"^$#/?NXF@OY<%'OT0\/WD..4L<F1.4U!S?4L
M*YX&@>A(_\:A`UNLAY^+$QRSK@(.L&Q)/PU2T4#M.02$>B0%YNS*)L%2&G/T
M":;J*.A,2P.HT]`02AK:S8<JJ,T3.*:H)06//*4R)7VBAJ&2856+.$0.A,)"
M`0A;'$Z=U`]J7C.L8N5"WR@7F.!=P:QCK0):R:"UM<(UKK_H'ZVJB10&<F$T
M<F6K/\F`BECL-;""9<4Y#,*AI2(EF^6[PF'%.5;%HN$0CATL92MKV<MB-K.:
MW2QG.^O9SX(VM*(=+6E+:]K3HC:UJETM:UOKVM?"-K:RG2UM:VO;V^(VM[K=
M+6][Z]O?`C>XPATN<8MKW.,B-[G*72YSF^O<YT(WNM*=+G6K:__=ZV(WN]K=
M+G>[Z]WO@C>\T!#BL<J[(00$%2")B`EZLU`=ZK2W&0-Z@6K8T#5%",L,Y#W6
M9`?RUNP<"1$JL,)^\6/>?AWAO>Q-KX+;T&"_QI<O-(DP&@JL&0"DUPWKG0*`
M0=%A-,RW"ZNC0GVCH1V"*`!9F2G(&18;%)?%A,58.!2$9`P,%]/W5>PU$ADB
M.@A.7`''S2J(AS##!E1-`<E)E@(2XEB%*-!78R.@`8VI8^,8U\4,5=;RE7=`
MK"ULN0U0%@$.(<SC/85"R2W6,1=6@Y&FC81DXWT38O88AC-;0:UM;:!/]CR+
M8Z7!E6I%!IX+."Z\I=,,NBG+'VDX@SS_"ZUXLYOT*;-L!C]C(7CS>6NF+4T&
M"8G@3Q#!LVXR4>HP.!$+@'W'5@;=/;9\04:F.(&/Z;N>:A5$!W<YT%T\]U5`
MQ]K'VN@3G\$B!%=X2!;DY?6QNC,BKIA@O00PJ)3J>6MUO'/:2!V6-I%04@^Q
M67(<FH0X^L"'1]-:/"[0]EQV8$YU1%LC`."0078=D^[X`#K+RC6(?`+J%R#`
MR=WH"+KTK2*#L(3>98D@B2&]@^()T7^J0793@]V'91-U"`57Q<1]\F[\Y)OC
MQ\YR<,AW[VT;VQ9@P'BZ+36G8U%JWK1:0XJ3?$\^R+HJ[XE(-Q!^M:;BG%G-
ML;8IJS!T>*.<_RNST0V'5-'SF*Q7#4G/,;$](D+ZGL93RR$WLX)NFPW_0HH"
MT(Z>5E"RT)3B+B?(]0%P,28TMJF(_7#/F\C.!,M0ZLN%0`6*U.4<)I&':XBL
M@>"[QH1Y<`A1`0=-%*P5EKZ'$D7]Z$'2<H"`*\T'15='#:I""2Y!IT*`4H&\
M#_EA]GD,($E+NOQZ3'ZU%Z'&6BR(V:)(H0!UM3V/%]D2$FIIA+4O*3-_F3GU
MU*751N;;]QOS02I>MD\BE,5J8"FOB_^-GI7'0'A\1Y6G"@!X+\1``.0S#2EB
M`?O>ST8*VY<TC?HUA@,HGROXX#X5*E7F-V#>Y.O'<.%/+Y+'-$!$)/_/LHP=
M\P#8BG@$<.P3'#`-DQ01\PT!VWC?E6P$"X@?+]F&KN21Y%F!4PR`KN!?Z[',
M&!A`65`>U_0+!'H$$_!>DHC@.^0``1`+070;5TQ%[;2=(G'>!?G0/E$$0?35
M+H@=TDR%-["?Z[B`2CB9QKP/H&B=P<G2&IS#O@G/?="%#"[-&NB5[\!!$?K*
ML2B25=!5D?Q&/R`A!-S,[2$1&!0"&9;(K)25Q+AA/S"0%ZI+*_G/"!Q!(XRA
MR73A&"SA'D)+]B`1+NR$];5+85S%`Z30\.3(]#3)RV0%6WQ+GMV,$?I:%2;+
MO-U,4]Q0&L%!`@CBR\R$%<:%*,H.(9IB73S_R6]<C2.M8K_\(2:VR<80AC_]
MQA-,`2I6#](<@+,4$1MQTK!DX7^0F0]012&<814D(]*02B0.HY?5B^BP4185
M@.8X4GNDA2)%#@7=P1S*$B$"PQ`"CZ7!7R_I2^F4U0466R,\#B8H8^X<BZ#Q
MV.^\(EC<`>\8R3GZ#(<Y4B&85;X,C>],CI$`3:6M(8<=0`M"2\90$`EL#E2H
M!"&J!-XHB>\(#?RU0E;<SO"`2/8-HYJ510,,("=9&B(6S^^X#EWTC2O,!.4@
M"^]%XTRL9%[$Y"`.3TWZ1"-Y`^S(0B_"C#Q24%[<2L!5"D;B30Y0ST(Z4B.`
MY/P,AL2TI"PTS+"Q_Q@_6H%5.N.\L$19Z`9T9%]9`&4#A4X>>F3OZ)ECB&/8
MP1K2X!(0T=>B3%`CH,I$J$PY"(X"?!(>4DT""H_'L*23"2,!>4$Z<=$+T`/O
M)$_JR"4G$5)"`N1B_H/LO)":2!)71,U;8B8>[I&P\.'Q4-!^$(P78",I:@]^
M'((&&MK'D."L<%(_PL^?]$Y=2N+XA`;[$1]'>J0R;F*W%(5+IA'/G28A`N8I
M#F=.;J+?-`W#)61Q:MV;&"97W$EV3"%&%DL6`<II\B4PYM%S#J-O`A%PA@FI
M4`H6=2`O;26&C:97/J9LFJ$L)&$V;HU8/(R_`=`P7N93J*5'LN7L-$)_@/]!
MK?6+''T-3Y*9#@#';@1GFS1C^YA<=1;"/8@`BST!I2PH08Y/@*:>(GDFM*`*
M+@!:1)P$%GT=9"[)A[J<NO!,98;D\P";+``H$:!G0C;0$=C"AJJ(+(8:&T;$
M&4UD$ZW!(;P)#?U;6&31!ZX<3L(/(SI5(Z(AQU`!<U[?;@052F8BJ4BHU,!,
M5#'?T^A`K=BH0*@BM%R9<=SH3/9#EG;9`-)2?%8AF7IGC/H8"GX$4/P;WF21
MF0H$'CJ!F/0#DY)3-%9H5QACF/0/1@0?@5XC]4P0HJ:>(QF90XH1ZIP`)V4-
M:.AE:FCG0F`-$<`007ZIQ*#HBXH/_"PJ+XQ"?/'_ASD$2,`Q`/-0Q)\P22E8
MQF=TQ$8@$*RT``FXQ!BQZG/$$^&10R-AQMAI'@Y0"@O4Q`K`A#*]:@+V9&J@
M0$<DP1+0F:PNP`,T@/=-*W^LG8TJ`1PX`10PF:Y.FYF&ZVZ,D2FXJ@^L:K>N
M*P\\P3PD0))$:[^X4V>0PB:=0`J0`!\HZZR^P6<DVC[$P&@D!\6P3`DPZPHP
M@`5R@G%LQ"T8F8`$P6A,!PNXV[^`097<PGFU@+<2JX1PW@TH)2S(`)4I*Z#,
M*P_]:\..K+'*:Q"X+,,&K``4ZY-(QDKE"WK!Z[#B+,E24[.V:U5T0DG^$V!9
MA`#$PJ;1Z[NVZA)P#34]_VP9_2N"("OXO4<G)`C)\N2?!!P-=>W8_:JW3NP\
ML(5E:&LH56T#.@\^]&L!>"NG!.M/":@+-NS55BL3>&N^S)NRABUOI5I2Q*%X
MF8NG64$&O8WBZM;@)A8]&BXU8)J[!2%@`-ENM0+B,D3FQD0$]5?D%D.J"AGH
MDF[IFN[IHF[JJN[JLFY8X9$<C-$[#%Z0S6XO7`@5:<%D;L'K<D'L$H-"E(Q<
MN*8@N,>789L,Y)XGF,-)D4&@:"X7\"Y^U&X5Z&X7[$.A^47M`J\<(,X.5*\A
M2&E"8:_5<6J7S<'U4D*&G0)>4F;]#>0O$,;X/IQ[105<!H4ZC"YCT<'G(F0T
M7O_!J>5!7X31T%R<DV6"0#!)47#!Y-YO#2BPXP8.2FB!J['!9$TE':07`-NO
MWD!N%N0%`S<P"%&0,@S?X):P*^D"!%N!!B<-7Q1:NYG!\,5!7Y"!*[`P"].!
M6B$IIW@"72&!9#QOL9T!TM*P"OMO#<@O!9\!#)N/*X&PHF&!#',PAGIPGP4Q
M@1D)#2OQ-CG':7S4XE021$G)DKR%@G6#).`'(B1:T[4(B*@&B73(%X`D6.`(
M%W&&37U&:)2&%X\`AA#(58V4K,6'M'(3J\7&583$4KF'P;2&P97)5'3$(O=+
M+56'<MR%"PC+IE'&>G''&,\Q?M0QH/@QI\A3;8AR>Z7_R""_PXGX3UF(2*98
MA,Z>`TSL1]>HLGKX4WXT08]XKP'/S6YL+<AU\8M<AQ#P:E@T2"=[VQV_PU+H
M`,OXARX;6Z((3]O1T""KAH%,\FQ4<M?*CCE8H;>5H+MYL[=-Q_^`%!Z?A[%1
M5$1=2'MI\CQ9X0F4S2D!B(V.U-3A<AKC1OM)R3BO\HB$\CLWS3N[*8>80'%T
M@C1'C8=8BRR<L0M\TP":A^9Y3XHHM#J'1I5@7I9H`P^5@D","48PGCJPV"99
MBU0LBS#Q+9^<UVFJ'I/4!)(HB4R/'I30EY5@R1@(BPP^AR*YSJ*"2@ML27Z5
MBNZ];U5XRLM,9*_20Z<,:#16_YD]PB-M-,RB3"AE)$&VS#2T]+3QDHF9?'4?
MC1,OO4O-I0GQ"--*<Q*XY-N4$$:J[(-9JW2E?HRI\.>;H#!7,`IE8`N32`*=
M.,J<:$6K8'6;:'5-0Z.\.D`ZK0I>-U(*/="2Z&RSF/67;(M4G_3@!*F=;`R(
M&DU$2`IV$F`/>,Q0[X"5J(,/C#5Y>K875(L3IYBO9&`GO-5%X`):XX*2(4*I
M-LM*[TL_^#013,M<KH'!R0F=C.?;Z4XEN0Y*"TH2,$X^Z/8(GZ53*#=J4X]7
MG\2^>"C!X$UE*V-/K@'7>(V[88R4`=#YQ`5[8U@:OLN^G(2,]:4&(LJ`T@O.
M6#>@?/^WFWHOOT7CC^+''-%,;A0;5?O/3)#,/XSE^]+W;1L,#3RXJ<)W:H?-
MIQYQY9TW(<KMQ+Q,?NM)S*1&:O?W?GLB%2QX8IZ-:4YI(Z0XC5+'[34HS]3E
M?'E?89ZS/E3X]*C0Z$@AQ82+ZX4VF;P`8)YE"E2XEVW,A$[-&!1"OGA#.]A`
M4OL/+H':41:YS`#*A;^,D$^!>>N`2DSXK*"(N(R41]X!C1-,(1347Y)W^X*-
MPNQWG(AJDM^CFO".[8S3&0F/*SM/HI$9)*``H<*/>V_W^\;:7E/F':0DM`0!
M))S$:;+H:K8X"L,.FV""@)/*I4LB0&)X50_/.\)X*GJ.*R'_3J:4>J$K>O1\
M^A0TTO.@J61`AY+VS4:L)`'JIEI='EN59?6P3M&X9:_+YR_G2I<:#T?JV664
M3^%&8X]SMG5OSI!')%OXN.,B!*KCNJ?GY@7#SP>.6Y(I0<<N3N/XMI^[Z""F
MNE@V0)EYX[%/:2$4#[S[(XF-N]Q1<>\XKOL8=]74CT?`0I0HXQ$E8?2ZWP%%
M2=M`2X/+3B^.D$<<>B*A8:O!@;TR*`TTO'?"4;_WS;I!3:8K:9M02@CA@K.W
M<H*GJ02-NDJ4V19^S#NMO/Q\%9,Z?`,)HPU+<+?8T4N69C1>/&9^4,:CT'X#
MR4\P9__X.HN;Y-<4_;[O$0"P1\.T_^$2?G14?$&6ZH/,>R<FD/S7B)Y'*%!M
MPL_7%ZI',D[/-S.SO#RI=#VRQ!&WZY%^2_`'<9`?71#8#[P004O:/^MNB`O>
M7.DW2OTS;D7`DY`3S?V<W^<=F/W5G%$BC(4;W=W=Z:0RK49N8R!*$(R]%/H6
M*3Q!Q)PCC=(`7T7CL_89&<8Q(L$GA?[&\!CD4WF_A-(1S-$;9!&3VA+LY]$1
M,"(-`&1[Q2[\/84IS42CY7[*;]$N>0%0G!"@F'[^M-?J[X`QU9%:[\`PQ?JZ
MEI'_0K\G38'K[W?J6YMTQGXS(;W=K`'QVU#G8^=]E8"$I]*`IQA,?`&O=#\8
ML?[+[#ZI)/]3(_P1""Q`0$#",A0/`+50@!00LD!#X[9PNY1-DS@D<BU%K95@
M#$PE0:)`<(A(`T<`8FC(7$Z;P%4=$FLWB`,J",@>K5-JE5,L!01`8T!(SDL!
M1R)Q!?!U</9R!<$&T6``D8#0QA+`0##`8#"`X"#$*$ADAJ8&LZ438]B2^!,D
MYF)G$'!@<Z#6@OG:<@!+$&!`4/"Z9""`L"0;P.+)"`&P16#`"Z$0,"!;X'NP
MY!(]K68]@"F0S+IHBX1@,(I%"TN+``[1_)Q3N]X\RQI`GI!64`I@+C:"G`$Y
MW0@L&%)@@1P%0P`L@.*L!#\#0[95^Q7GD*-SGEJ$:V2.V4$;[3[_0C@`+@'!
M7X!6G<3'HB6\7L(2%FC)SITA$D3FM?`5+X>_5\<@3*Q(3=<EF1%'7*-F]%\L
M;AA_'G!EK(5#&3Y_+GAH])<LE]\8S<0Y,,4O@PDL&C4B9@!<!47?C<1B#AL8
M`P@.E""IDTB!NANW;'U[-Z&"`PC^MB"`($#;.!WQ\41)40Y.N0?IYBAV+%HY
MCCK23(6R"T#$S9'7=7L!3J`P;U`_IY3#-@?;LY(!FU3VI:/PX<2+&S^.7&CP
MY,R;.W\./;KTZ=2K6[^./;OV[=P[ZNH./OQV.^++,R=O/KWZ]>S;NW\//WZ.
M!`L$Z)6/G_L`5W7S=]^?E7\"#DA@@08>_YA?`9<@R&"##CX(88023DAAA19>
MB&&&&F[(88<>?HC=``!X$]U-P@V&A&/:/7&=+OW588-STQ"1AW$HYG#C=?NM
M0\0R,1*8HX!!$C=C<0FHV`B2S-4HW8Y:D;"@=E?=IXYS,/Z8WY'_\6BE/",B
M5P"5[*46``[0`=)10H$P4%<!#3#@B13H'-=;=:I%,<I!`"B@@',&)))3<6KB
MN,`AULFE2#AR(0"`/V8:1X``#_`(P`._$:>+I4JZ,.AY#(#%7:?&'0"H<`"P
M*12JSWW39)_CW"3%IM/)08,GI#)7@``'`'!`H?Z=VA]VMUJIP')N"J`)*P\\
MH(0+KLB:7J39;/^'#R1$],$E(886=R5VGCDFR[3O!#M<J<`95VT.Z5H7+HDV
M-,`E3\<1\,`JB#97*;K;(F=:=%P*MZYQYG8D0'\%%_?O25HM]UR[E3RVG;3O
MN,#CP,,5X(!>O@AX,'0)>V(Q$1]W<HM'<.K@B0*7LH?Q%EMX(Z)N_7T)\4^C
MI-NQ"_B<7$2_XWJ)3<Y_E4"`B@#(VDL..7MTQT_6/C9GTJ?T^$680NFU;B_K
M'NV"1#^YJQLZ`;_P*"V.<<W*?0+T><LHU1R7;T=H5UM7T6)R<0C,Z$@M-\-0
M>$)WCTJR432.H^2,1K!HDPR&`PL;=1_:-(IM**!@_\V*8RG<3?.Y\CC_/G7A
MG,YIPB,XI@V&-\=@/G'GW;;>G-!SLBXB-NO6?O7`N)OB">-Z)7)JE"<Q')^D
MTOSD0#`.F"F9`<WZ8T=;Q?(`R!$X]R=-LB<)<DCSS>*2!`!)+);K%7^Z4HA<
M>_J:`P)!-"W)8I]KWP@#\KM_0-/0`!(<&S?X90<8@(X?@EA'NO[!@"OXHA58
ML)0?*.(*(N"O:2CQ&002>")C+"(J!5367XX`@8,$H`8`D$((31(WW8A@`8P(
M@!$8X(`2J`*$GC!-"2.SP?T%@'BT4$`"*4$7!+!-9R^,85@8F`-+]8$KC#*"
MM09P$`,XH&XKO(0/Y=5`8P0P$S_1H$DF2`P!_Z0A4UJ<XCOHXJL%;M!%9>.@
MKI1Q1<?\*2M*3%\3:4@OEW"*46\L(3X:$(TE1HH&,"Q!7_20JT)]11D.D`,T
M]L6%8X#QC`ZY@B/LL`PQ7@%\J$J(/\QUR09DTH*/Z\D1',&`2;2``>Z[2WP0
MP*PMN",,>VH4!IG'B:H=(1'7N]8,@E,#&]+E5-(HF$.^T+%T/6`)U8I@%41F
MNEJ9(%@#D)1]K,68%M3*`+FX)AM*H0PS':Q9`WB`#.AVA,A,<P2)>``E+KB$
MNF1S!M;;UP,,M9\'#,.8`6`#.<WI`@SRRBM38V0"?I-"9^7R!6P3A@ED0*XV
M'*(+G>#F.Z[9N^`PI/\%.=1!0Q_!3W,MTQ2I20`<#K8+CM;%&>=BG`N`)TX6
MA/0ST:SG2R,90AGV::8I[<\_(<I#0(VT6B6%@U:,2H2?FJ`A0[W""-OPB).A
MU'2\#([I",:">=:J!XWH$UB(>H5J-JH^#[6!N;[J5$AZ3EWHX(Q1W/D.(\HG
M4D;L6""'>327KC4(O)PH]MZQ@H&:QH6-RJLH&R6#9!ZBKR?IT\-RP#Z3/JUW
M#(AI"#7"AJ4AXHVE+)@*7-"`M#Y2!U<(;*,*"@TKC`&SI$WJ$$_!`M,N`U"A
MI9CCKHJ$8;T`=#VRV``<\85TZ>,D#W"D</IUL$YH-J,M,.,OU:61+\B6"(S_
M!4=AY\`"56GVM^U8ZTT]=[#INB"RC$5M>*E;6!9@3`#H^"Q'`Q'4[U;+NHW2
M&%(Y1=LK))>QZ4+)3[(0B<72X@R8&,[!R(L(3Q"@5Z+%)&+I]5W=,)AW5!.,
M6AV70M&\AW6F2:8KAB@BGL7S"U`L07DU>XAB-=2I(#X5&*;9V@3S+AK@Y(+I
M2CA9)#1.IC*]L>,X&Z-Z%0*\C1JI"5JH7]-5"ZX_*M4!/J4T'\?8!0C@&6P1
M\1<1&3DP5>`+&+@*J#)!,J'>*(`<.I$NARRL603SZ[F`S+G^B>&I.CN$FIE,
MI>KR"+N($,/2S"RB+^A5QB0+;Y:CK!70K0M0AJ8%_Y8=?4:`'C5H"Z6N?/6[
MYQPX`+<VJ!2E81PWL&JE!IY!J8`]&I0:]CC1CXY1N$3M8EIX&K6W$.W82OD3
M3D^KG+9;F7E&H#-8=*P'"4C?$)(7BW-%4,:]5-=C)B711AB[G.L0]C&4V=J-
M=>3)MV@H]HI"!QASN[%8^-X2V%"F$5N+`>M093-/5BU`EDS&"BOG9TYV`+:-
M[0;;@H.\%<;N5:H(EG(\]0&@,&1E?2:$+$!S]V"Q#E$:I89NKJBY)Z:<(K!-
M?G76`2S^_2_&(J!I7#NPMR';<$''E\B*8%NV\*WORN%TD>D`N<)FL*V`7[`$
M@Q9J:T<>3Q410B^_O6"[F__0</X>@INYLA:V!SQ$TAULW/D.X1$8H6C14KMD
MVC-7UBF<<5KDC078:$8;UJ$`:)6'F+PZ@AA5D^('B/$6<D?!`"0Q&"O`D@1?
MZ44"-7:0):!`&9^2@0+D'AQ2_:`$1O!+WTUZI+Z3:EGP(@*?]K2$)!Q/9_`*
M2!$6`(O+._(&#'@CY"LA2KP7X.^K/V@N^GZ#-`A`"QBK[!`@W]R#FD3T2T@D
MDN0RS#))Q`&V-PH#7$\CAOEQ[X+PQNQ'D:G(N/`191(BN_7QAXEFAKA<.M5#
M5D\"O).>LSI_C!4HL0A'$`'[:#(*\8$PGWH9I`<W<(!#P9^"1DIB\#IH@/7]
M<G[_.<!*@,``U<!Z[Z='O&<4)T`)I((0!]@`[.5^Q4=8_/<3QV=1D%&`2<4H
MD#=_Z&=_NI8_NS)0QH=\^-=/1]-WDO`'9+!I589&Q%8O5$8/Q84C?P<-=.%(
M&!.!B;4`[5`P^;-)#[!X)[%I_;0M)P"$O%);NH%W[[(LRU("]I<U0&!1\($-
MDN-9*L(W/^,)?T,ZT-&%,<,IZ)("8Z5@82@/G78?T#<GDI,<G=,C>'`U)[(I
M72@H<J@,D7,W5`*&T?$EHR"'?*,@^.(82O)./R$K>JB'%[,I,:,D@?@85$*'
MP]&([Z"&P[$[6D%T$76)\J!VK/.%BG,W@$,";O@.I:A-_SCB:Y@(-+)F`W\Q
M"F0(-1@'!F0GBZO2B'#(,1%%(:N'#?L!(L-8'<)#C,=((+=F',NP+2R"C`9R
M*L:E(66R-L;XC->(*=BHC7,U>VKWA<5%=*JXC>-(CN5HCN>(CNFHCNO(CNWH
MCN\(C_$HC_-(C_5HC_&17I_8?DM2"@8!!OG6$&FA%865B=Q28S*3C^+8')`1
MAG5`D/.A5@H6$=#"5<DQ&&CC)%T3(()BB:^E'0J2%=Z8'!6I'3,ADM*Q)V)(
M#A1CC2*#1<KPDE,B:P_9,"+3DC9PA8^QD6EB*KRH##YYBQ>97N4A(OG(`O[8
M''HD'>$"D=-1"71!'Q[Y$TH)*?\2)XQ%D`*3\`@J0PN`I!K.M202MVVFQ5+%
MH9!=(Y;($%@`-I7+Z%@:UA%1<I8$$('75$TIP#8)@04?DU1S@@WN=1QG*0_@
M$$]I.1TW21TI*1<1V1&"*1@APRV%\@-<0`DD>2T(`$MB$"X*L`5T`47`4)>L
M9):>D$]Q,"(62`OV868$E9,TPEL]47KK-X/"<7=%<%A[4I`O!HB,\B>-0F*M
M2)N,R1S30#PF,AT^4W[4L5R\M6Q*<PA5]AS+=53S@2[)(9W*`"CCAAPB0`O`
MB9/5J2ZF(X%=8`9&TDB^1&O%(9R>T%'OX)WQP9W?B1SK*1R021QQ40@DHXQD
M^%15$$__)(1+RI`-N1F1@((>*16>;9!88O":[4,_EG=?A^>+R[%#79.;*%,B
MTSEQNVDG/%0=/K-!T[`?>"`&\(`-1W)PL1`E!S,C6G8T9N89SJE-O#4-06$-
M>X$2G@@H0],6%C4"/+<");`?<BF3ZV2-*51LC[$*@$`Z"M``0R,B,E`'?W$D
M4!2C(_`B1+@*G*5.3&:8*3-TG/<EB;`-LG@T/%$I7'.CPD$(I*F3/-(,U_`3
MC5(1SJ`76M((._F%=9(DJD$E3CHTW;D@>9"19?(END`//0H+/SHUN!",=IHB
M*5I#4@IMEBDW)'0R]N9"2$`\;106ZY"F@T-$G(H$<[`.7?H7_U]*$M-3&:RJ
M#*024?,$&UWC`H!0%+@0":*T!(BJI&9W)'XJ-Z52)(/A(B<AEY#*4;)2IG.J
M"V?S"L3#)+^*F`8V3/5!#);B!-UUERYV*D(D#2A0;'QV*R[:"Y='!*:1!.OP
MF02P@2FYJ9'R!CI*IV8A"4)@!5>!`Z$*&>7F#>":,2;`$`K`:6G**P''*M`0
M)D#V&#!D*,.%<X1W-.:J!I7P$76P=U<&&RE$2DYX0<FP'[HJ8W10!;U0'_B*
MG7G5)YO:$63%"HV2!["P2*N9`'>0$#]8`RB@`B0`+"\@;'QY%3/0)]&H$IS&
MKJKU&(_@/+K@?YD@#0#V6S#;`_5:;/^OD`6G$!FQN:_.$V+>2C#.4EP7B@NS
M"EO]DE#J)Q0I&[1!"C)XHZ'P9U0[I+&0M"OT$H8D(&E]<E^0Q2.&JAK7UK,O
M`$0?.R)!8'68$%I`8#]#&ZR?P08)X012E!F/D+5LQI4$0PDQY+@F.P,PRS"L
M(K0"&SM0N0!:<`I9^`7?$;)BX#XVX&;T%F:0)$8+(%=8T#TX\`?GPG'72;`'
MU5FGE@A\@@\KL+JU"6K$0[#.<V-5$QRS)@^'1W+!T4O5PJ[X,'=?^*]O6S",
MQIB.)`FLL!R_ZW2^BP0-X:$FT+GV<T'X<'@,!U4OD+Q/@U)\$)&\-8/)Q4-R
M081+`+PIB![_W$8R">1";%!HX@M8!+"_)T656%`4":%/9JEOW\L]&EH$<W*[
M)!,RVBO!&`NW&#P&;2"5+Q!"??(=>>L"8,FW!G!M\GMDK1,<`+R^Z%&\BYM$
M,08'G7#`UT9#E`%CV,:NN-99*1<[AL*R!AH<<9H(':-9'>-S4\:V_V8"=@8\
MC/$%SJ6[.]J[!77$=9'$0"P4@*("0%RA&"L8$>@YT0M?QN$9JN)"$'9VM)D&
M,&!4C$.F^!I@6,P*4BP<7"2C(G5MP94WS:(_'8,+[--;;&N_)T+&2T,R]F;!
M%?;$=@P)6YPFAN*/)93`VO07_G4*!FQG5N:IK]I=]&9I1=#)275M_VG':/]2
M22/TK[Y4*9!Q;A&%5&%LBX.L0,3'Q>;".(?<.R)%PT"\7+3<$W3,.VP0##[,
M<H-6'#[33ZC5"4B9Q3Q`R3#FNAUWKE<0!6*@$%H!)VC2"=I3Q;H1:-$F8T<<
M#@8QS;RL<"]UQL[S4BIRS@(,O6Y&-[PE*\?#0FT\9$R&#*/@1&MUQ'SV=(G@
MS>7[Q7O,#&9@0"EK*,5P."S`*&"'7W_Q1NKL$5V36>?,.'!BP0D]P)#,!(&!
M=%^(6^ERS'GL-J#C8@9@/4.TC[5ZQJ(\PQ[1TF.0#&^TSTCR6I8`.&W0+R3<
M7$4AS#(0T=7B#7U0!_WCT<MAT>M\:5>F7/_GK`,YS`4"+6#N[%W)7+X&]L=4
MY;WN"UA\9H1$_31++-&//-:,!`SZ-00H(1?!(7$%H,JE$K3!\=-3LQ]F=`F$
M0-8QW,7.8D2=4`7J13P2Z`7A),WANP2-A`?=1S1V1F+-0C?!D6HA%'\\1V()
M1AXW,"(#[05M;1\C*C)L]LBC2PDM!$QU?%$NBU,CI0UR?<VKQ&=Z9=C5A`5Z
M+2)F4M`V8-K"^-'E_!A?($4LL"#;A5><P#9H`MN?@<)WLL-AU2PYDW8U!-KG
MAB415@EB/1F"+=DQW36X!9U&L068A0U&]2^@IS/+,<+Z*PT3-1@DUMN5YM>%
M/-/*!,3#C078P)7_RZT5.,#9=R=@]!(3QFO77(P<4:F^ZX!]./D04:`RR9,0
M40)+&QCAO^4$Q(D0`FLT/[@%--#6+*01C>0\;2$`";0VF)!PNO#&+G0-+`T%
M/VCA0_`51$U\IQI+1L%"S0`J[[!#ZLL3^P$6Y;-Y5*8RHM`&BR!$U<!"(<8(
M;O(`J-E/E5MK-88/PQ!7K^7BSB(,E,!*,:X(LL>9F)D'73#CQ:8RQU=L"%7D
M+L05"T"$':XRN2#F[_`FE(?CEU!EF,E>F=!6/S@+$:[CZ"!$K@!.F1!PQ`0#
M2U`)PP!%;P[D+SX,"^Y"R&KHL%#A[2-&;T<*R\;GG)+I:\,.Z\(/*SD#_QUA
MYB-N=6VUX+FVDO#W$E2>Z/(PY[Z!"8]02Q=MX;S`KD)G.F96*/@`%GG>#OP0
M&8RPZ/WJZ%D.Z%FN&\$P&8W@!)#1&()P"5E>Z:!E2`GWY3L4YHVQX(0@L*[.
MX$K."\R^CGAZC\CQGOK!E].!1;MB)"<)B%LM(.B>[FW@F`[B#[4J[_=.',;I
M[T0BI^VQ8-R1/+NZG@#/'<H\(`KO[U>9(1#O\`%/\?>NXN@='W=WG15?(+1X
M(9?,\2$O\B-/\B5O\B>/\BFO\AJ2BRL?(OF>'!Z?'I58BQ>J)!=*(S0"\R[/
M\^?XULV%\SU?'"7DBV?"&)\<'BSM+/J`+,7Q)_]Q$O3E8]-"3_7RR/#P4?3:
MD?7KD0(](4M;WQQFTNY$26(@'V'XPL15K_;Q>/7N@93E\=+R$='M<PP;#QWV
MF1YMO[;.T7[*N/9_#R&UP)TC[D-%HQ`R9.6A'I^C3E:8I`,#8>E@,5RMP$HT
M$`Q5([#.\Q`+<'P>$0R<@.3'!T4_A",PX$C.0PC'P,FP9)?`O@6`L`O'H@9`
M("F];OJ%R1>=CP6?7VY[,D74^%_M4*Y7:TF-Q"-F+FRY+P8'M<V4W[2&^OCR
M0T;R9/I(@`\F0>C+0/L-;!1\$6ZZ,$)A4BM[\D-8K2#"3Q)PW".B9&;$CR,1
MZ%3N;V9AM0L,L_IRAY?_0&BLF.D1("`D@P(0BT)`"3)`+QS+,UW;-Y[K.]_[
M/S`H'!)[AL!*\'H4(`@#Y,!X)1*Q8_+%<!V4$`$`$CA`!@PK>/D2&`@%P!;2
M:`86Y0<Y83]8"<POE!X$@!?,0,.+`2($$X#+2X```0$#E"1$@8.*%UD`TE<+
M`--AXB+;RE[?WQ]"@\L<A!V$@EU=F<-:6$P:("H$`8*695N!`A?N6-F9F@RN
M7!AG3$$P`73HGRSME\M",.'+-W.VG8+J3)KM@#.,)Z2=.B22@1593.1DI=C"
M``"`PDLW@`L*0(DR9865(@H7,FSH\"'$B!)I#!@`S,N#>%K(!(M1\6*605[2
M_S#0I8U7QB^ZPJ'[]"#,-P$*/`78!%-).!A=7OAIDM+>)P.2?N9KP*N=2H!C
MO/1,&G.F)Q4I(^6"0[.3RUPR>*7Y%HDF-%T/:"(I^4(;HQDJ#C0(8U07#`(.
M4FB-%<"JIP,%"H'SDC,CWC$#?OZ$T9(9NT](IR))X"#`H\2)E""=^>*`,S.R
M-CJ9Z/DSZ-"B1WL>@*`?1HU1)'TR=-JKWY%A7D)2@K(NRS"+;WY):)AWSMHP
M:!=634B4820D'D!!>M13(=I=;?MF1E4E@$62TR;=I6NZF(Z_ET1FI.MZ\2@&
M!J197A#&7@=AXV6/4=]^[.&#M`\B?$YW5D"IQA@5#/_$L9U7GPCP"7(O(*")
M3JR1-B&%%5IXH43EB&1=:PPLH$(,&GZ3P`,NY`:*@Y:(A9ML8KC$&UIN.(43
M7_VY``]W`JJG3D*PA%%`1LZ9]$:)MVCU38P^":=24RNXR`POX\UHT"-HZ)*/
MDP)T]`1B/)D"$R:%%>""4-TI4$"3(]#F9#A__?+'"H,EE-YA.:JVF$:Z+-#:
MD^KU&<`B@D11P'5:?(@AHHDJNFBB"I2C0`-JNH"`>`=L!H.C"4!J10,+`(#`
M,FD4P,"8^\Q2@@%XR)%0`HM$ZD0P<JZ`2"8+_K/JK)B<`>)9_QA`QF#EB>$*
M>URX4LP+Q]IAP`)DR(1)-K[_UO-JJY@X8.L=D[IJA0(.(%`"K-G:5=V>G%I1
M[2$,U/%*0@<\H`"7HY;J@A_ER96``>H2H*Q]OEKR3P'9>`ON@P&<F6L4BP0[
MR\!AM)*`N^\E:P6EXL+`+$>Q%EEQ,@/90ZP`DW9T"!D'3_."`^]9"D/%C+K\
M,LPQ`S%``".LUX\)_8!8Q0PTVWSCKP4DQ`L!OSXRP*]1#/"&(_P`4`#33+O1
MC]--%'V`"U+WT\0!<,&00`!-#-*/#`$@<,!Z\-4,`P!)E]'&%VC70T78+VC]
M]"]&C^V(SDR[`+;5.N.<M[WKW=W$`&BKX+?=:_.DM]->K]!&`C"Y;0@`=ZTA
M=PR`_^M44QE;5X/WX"O4?5D;6$NSM>!D&]+&Z*/G;`(!8/,*R=EIQ_Y"XG"/
M_8O.5/@&M<S%&W\\\C?<"D3(R=N`%/.2.Y]HE-/S`/T0RUN_/??=C^;`JS[L
M"[;WF%[:PR$2ES]A^NOC@)80X%?G/OWUVX_#F$$0O_[N/S!^?VC^!T#@F6`(
M^1L@`A.HP`4RL($.?"`$(RC!"5*P@A:\(`8SJ,$-<K"#'OP@"$,HPA&2L(0F
M/"$*4ZC"%;*PA2Y\(0QC*,,9TK"&-KPA#G.HPQWRL(<^_"$0@RC$(1*QB$8\
M(A*3J,0E,K&)3GPB%*,HQ2E2L8I6O"(6LZC%+7*QBU[\(O\8PRC&,9*QC&8\
M(QK3J$8USNTSF=-<\JKQ@P$TJP9%2T9#/N6HHX'-$R,HWU[$ML9!3L@QPIJ(
M`,8BD<K50#P]0$"-;%`T2#P@/>QX0"2'(`I/,"<&#7@`?Z8WR2]@DI`\!,`"
M9.*H'T%R3ZNT3S<B48\!)$``6NH&KU")`%D:`EYFXQ,$?`>.5!Z,>:H*32*!
MR1"Y2,\)F<2!.AYP.QLTX!-T;&/92LF0!8R%'UO1YO:J:3<!"-*4.4PF*:T0
M`&TF,B&I*@B0-E-)1S@`0N^TVP-DL:=QRD!=WU3F#D3Q@(/P1'0&2-L!0/<U
M.&H-CN"X"SI'AZ:#<D&A=--%0S'_^DD#2&Z=;0$1H=+VO$IJ3VK!+-6[9@>7
M.X)HG84@U-R*QM%ITFUN!?AD,7>A39PESJ*F:V-('R%1A$B4`'CD74+APE.:
M5<D38J-C2J,6ER.`J*A'-2<*T>E2,6ASJWXH3"+K,4]2UJ22.B4#*!_11G>M
M8PV*!((!%%#)ZB!@H`I(I"H'RKM.#69:H*RK-!W$G``XX*UU9<!=,>DHO9:!
MK\?\9`,`JX)4O8M/>QFHYMQ%$`>44P;YJF1Y/@DH3":``9BL"8E2HEFYJE.;
M"MA"`_YQKT-([[5T=(5!,(E-4GIA,(IE["$^!,K+,,$`G!6LELQZ6%H\8&1\
M12SO*HF9_[%0P@K</)=I%P0,;6;"`$"JQW)-NUNLCA"==0W&5IWP+O7RQ:-+
MH,TG60!.KB(BD8^900#$JU.`YH``>JED>X<K4!=4D@[2<48B@Y%(*/CA(**E
M)"(&S(@_K!,:"&XN*0LRUFPR19N,G<$!BE9)/B5R"V<C*SC,J@Y$I`H)6]TD
M5PGU+HM(SEU($,6MT'D.<,YUP@:V0F'?A)&#K%,^!T"O7GVK`KGJYIB5W,=`
MUED+=KXUO:9UJPK<*V7R9O5=F&F>1P'P91?@U1YFG?`1,%SF2V9D5)6$A=W`
M-ES#O-4'"BKP)7%RYK&:EJ.?;`(ZT>FND52YE`)];QCZG)T_!/_ZK1LV,R<\
M'%C\WN(!;4VD]G1\Z$%3P05;E6L)Y,K1-W=V%HH4Q4%T_,WH$(<VI@V#'#D]
MX2Q_F*N$)L.KN7HKZ;K&!&O6L5?/'%9;$YO+)L2T(RY934L_@IL!=D8E.0H#
M9YLY,^O\L'(>K6H9=,&6V*2C)[BY7DKJ.25CC39/4:Q5*BO&T'MN-4>IIFY'
MKPG2Y$;T#/SAB4\>$\5T9I!9W6MO9`=/KI;N+#H/[>]5#Z?5LWE`==([UO3>
M&\43E[373-,I=M];X>NFS'R-+<)M$WO-[B*HJ7==[RC4&M1.^L4G8;VGT2Y/
MU=Z\C"T%@$V)&;RE[C:WJSNY7Q2GBM#_[2XWOOO\3W\_.L_$Q<BDKQ`#TQ)T
MVYHVJ[NB3FRYG@]I3Y:!7&_,6)*[E=4/3_2XG_Y>6@>8T%#(]3I5#I=#:"*]
MP"[E5]W:B5)27.0CK_.]HUF03_**`1":L.0(#P/#JT`[))JL4"L)(E4[5)*.
M%.C1^P/T,,@U#@G8A"(C"EHY%!KIB#>UYT&/!!W/L[-;19.'44Z%-E[[.X!/
M)HW-^M5;M58)66_"&Z+0G_/9N#\Y!CR=S7YZN1X737X8<L4K;MHETV:=8JUW
MJA!A]VX:59M7)B7;B^UW$7[2D>I=A$"M)@#<OE87OIT?`=;O@O8O(04D0,)-
MIY[/9.6S'^L\_Z0,!)='5-)QR14BI%9%\)I<6)K.:0&&X91@H4!V4=\!@I9O
MD<$"7DL]F%8P0*!Z+4,,+*`QL-QF=59W=<Z;O0*&?8VE-<;H99U1-$%=N0J`
M=01G`4EM;<$"X-8A[%\`4AV]S-4%-A8#=H1F&9?8S&"U!4"JW$IPF8$3]AAQ
M81(W+0.)W)<26HMW'9,!?N#XB1#.X(W=A.$8P@6A.$[HX`Q-G6%U3-3IE`[3
MJ%08-I,,Q"'OS&'DR`[4E`[2*)0>IEL4U$37W&'K/(T=OHT?XDP</@*:4(37
MA!1-*6)!*6(<WHZ,1([8P!2]J.%E.!3$G,X,@(WJ8((D8DX8+HTB\O]A0I43
M)$ZB&-H:3'E$0OG&*>I$VER.C,A.51W!4Z5B\'PA,`8C0_2=,!:C,:X/,1ZC
M,B[C\5R$IS`C-$:C-$XC-5:C-5XC-F:C-FXC-W:C-WXC.(:C.(XC.9:C.9XC
M.J:C.JXC.[:C.[XC/,:C/,XC/=:C/=XC/N:C/NXC/_:C/_XC0`:D0(ICY,RA
M01:1029DLJV00AHD`$;$0Q9!\%'$>$%3`47DA7R>A6#DZ]C1_`2!4=&A]_`#
M3>$``%Q+SJ5D2EI2_40DWAP21]X`/U2$#F"22MZD?,!,3$H#XNC`3N:`3=YD
M2N8D,I4D$00,?[E+#P0,1VF*]MS`H('(;1G_90W`05O<`!R()`UTWQ]ITE/:
MT?GP#B050=O(1:D9SW;1A%G<GYAYS`HP@*T<B@P$1PVP)/U<@D?`2S^T0@#R
M!RV-10%@QGL$S!\Q8>9$F*V,17[%@%U*":/X0PB&G<'0Q2]XBAY`02S!I<'P
MR55QI8P)TG',0&/6Q6<`"7\1`?8(7Y?@#ZF$"`]`2@P@`%7:P(+D0/7H0(,0
MP0(X0$16)'X4`;C,ILSD9O`UP&`>7FW&0B31)0V,IO>8ID<T`.W=3JI(SII4
M&#OP1"'\0[(U2'4XYVTFRFZ61VY>![C\0F.LP2=4Q[7,Y4\(`&]FIVC:IE8V
MQ"[)WN*HP,T5E"%4_T0YN0'VX$A:3`)/GH/Y"9(<88Y]1-WE":=Z;B5<@,'2
M2`--TD!NJ@"!PH=P&I4#M-%'\$,AW,Y"YD2"@D,9J$4YA:?S-(A:%<>S?$&[
MY=LS,68"W>?'!.#MT,)37B=AM93='!<F+&ASTJ?+<&@;Y6:#H`!\[((RH8W6
ME>?ZR:<,@&=]+@0)J$,]`(-QUA4++(`LU$R^\(.W`$I!/$%I\4F+S<81')=I
M^,.E^`$=@FD<H$VK"-*+\@%/>,H"0,$[T=96*-/9E!:9(<!N+L(\8(&%IL0[
M$9;5E,`^V8!L+B8X/`9BO59-I`HXG,:KA(.<3HH_2`X"0`QNY9<"^*;Q-/](
M0=Q5V:2:<C"`^6T(#C@G]UQIAR[>::Y`UVC==<;"J/Z;L.0FC>*`BEY(I*)<
M@^Q+1XC"5?[I#-C!BZ88.T`A)`RIL%:I0H".JH*#*70$8)2`5?3&AJ"2@P`3
M87B:BS5EO8G"2LE5UWBKO@3*.F#&_%T,%'"J=$I/<DZ=5C0@CT!`'-!A;A9)
M.QR*IMB`:;Q)A`*+F\@!)-0K3KCK7;Q#.1V9@\C"L"+/)@'*&M3(.FULMS03
M<\[G`&%K=+2&U[7`66@!G^RJ`/+)8943L.I'M3+*P<(IVRCF`H"@KJQ@<LPE
M&<CKS6;G"0(4E8)&-1G,I+%$5A@,)X*'9?2)S'+_1SNP`2"^R9$&B;>:0)G<
M`5Q4PBCQ#@L4@@"$)8S2`$%<)2_L$L.<9L!JA*Q:BB=`%XOH!UUZ1=820+K,
MSZ.2"&EN3X.(3;:R`ZNJ@_KT!5`BT-'*%8C([7#HPKY`!\KMJK6D9OP=7G]0
MZPU<+(7`+:D&+7%1I[<P*=CMDO5YKA@05^9@+FU:*Q'@Z1K<BM*J@<$8PI1H
MB6I$+8$T(.]XDO8@Q^SRCL8N@2#E%\K:C3&$@VD0I>C&Q2S,QU$4A!20[>5R
M""-(I0ULABA,WDI$QR`0E(E0QO+<"&%)C.T.`H*Q+LS$K%+N0HZ)7:F%[)0.
MD.M^P:V`RI2:Q-'4ZA*<_P<++D(C/BBTBFSFHB]H8&_2%H8BT2)8\0DP"*[I
MML:#?*6=U(#F+H3V`&WLIH5C((Z5;$B^W"YB$$@KF,CM9()29<0&E\'G!18E
M#*#V/".GTM*!]"S8[L6^?L=:W,$O_*I_/(F7)@)/^.S4*<CVRFS*E`$9C`B;
M5HX*U%(,2,%EY!@!NTS,RL%Q3MXGC/!<SFC4VL\%Q^<AK&P8'"RF1`?_7M)#
ML</<5/$$TT`%CX:8#7$`]T<8F(H6+"\D\(K-3N_I&D8F%>U$Y,OPO@NAD`HE
M[`.)<(M-ZDI-Y->8&$4DP)D6G$8BG\"'T%WY2L.>],,/FYHM749;($!GG2<D
M1/_6:Z&-;,U%+C'`T>9717@+J*1`'8A9/3@`OKP=RG'E7WZ>E[H!^)"3081@
M-0F5X27`J$#&+SQ&[4`<RXUM13BR)^-$*$O.*HW@F?YDD:Y35_+.3+2EV,"!
M6S9`^!ANK`*0(%\279"`MP(*WM*"5'(3Y5`784:&+%A%6\:%-@L+("/*XQ*S
M+:>EP2Q`0J12Y6@(.'C(-]ORS<Z!+H<F-ZLN!4_Q:,@(5EI$S\SF_U:EY%#T
M'5)$OF4-2%K-T4C._QJ5#\PD\P(!WJH%'7+T(`"@2RL02?K`20JE2LKJ`+T!
M-AOL[@Z"@RZ!30^E1-,L\$@$``9E4"LO&0D->15D0P[_M0P]=2TRI%3+FQG]
M]$!FM59O-5=WM5=_-5@'XR$N"OE$1%EC"#"<Y4.D-4.TS0BJA2B'1M'D5%CK
M$%\J"B-^Y`[$)%-?"+TLJV?L"U3#]2P4+LP-M@_L@?36-0T5"H8@#1&X3O&X
MSALO1&7K`**N+FC8,&/WT'6\@5'QBNTLU%-AS7I\7N;P"J'XQN?IA>F,,0K`
MVO"@(6J+%$]4@MAXC@S4#A54@TCUSHV8MHEXHD,=P""^C6W_`FYCQV]35!V:
M`.B0#3\@SL^N1TA6A3`EU,[X5V?I=C&0,CC,`W8+E7.O`'>CY]P8M_2L]N.T
MQ4YW]@I11<#HG"*<Q9C0QIFP_\?/,H?.N2HDQ2?:.`%WNBI4.$N(K9)I<`(4
M?$OW/HHCW91WS<*8Z*Y8X@1B:4JL(#)O1@P8A(T9-(>!BT$[_T(PA"E\&">@
M.3B)!],,SS?:(,)@4('O,4=V*,`\Q.?81D)\&@.0O`&!\TE^-^!W>TT<6ZR*
M%PL<=.^WU`P9_'!-D`"W+;AL*<)"PC<.70>>L$`BN(%?%$F1@*N_DL$Z,+,(
MY/&3($4XC'D'TZ6H=#EYML@WA&H9N`2]J$LD4$:6K1Z#G0HG>0U7P`A4K!R>
M<$<X3$6+\`(#&/>"Y-?JS0]GBX*YEHTQ:.^&F#1WE+F_>H)<]<(TJ3FL6GD.
M8?G2<O^F&>=(VM[%>ZX>7!CW/J&YGO4L>'B'&)0ZV\"Y;5@G.3\QW%J+60SK
MGV_(L`YZ2A3ZDJ3!<Z3F;19*]0$3W15$K%]-2MR&-#B`69AN;<(OJ,N0J*O!
MUN8-0076>Y['?TV>L^C":9PY@R@!D)#[E,CZ!R^!B-JZ73#OL*^#"IQ[.SRS
M)IQ"$$L)>/#[+^B(N9&SH=\P)"349MB$9WU[G@=@%"@T>)P`E(B%V.@GS5CN
MNF_.IV>[#6W[@*J*7JC#CZ3&&@P-F7U"'*#$_$&&)WPO`*<\;WC'*X_\%A^)
M[QT7M\+`7%@$6JT\S:S!9H5!<DOHE!B7T)>'L),)R5^'L>O_PK%T$MG<ILAC
M@A>D9MHPX928S9N0F9XT`-XV!]`O[[]R,<>WT#1X"C#(9BW10SW5PUZT?!(,
MS9[*>1G$$O#MZ:3X-SG!P7HP"^+8/;2T@=]?P:N\/3*_SD`P9=%XS,O&O=U\
MDJF`"J60$Z5@O1-0^\Y%BN(/_H,D>@A22NV4.?&R!0"LO6E\"%/2TIZXMD&$
M;NK7X:)G#;S<S@',1#!L_D#(A8VGS.M#%2Q4OOK0T2Y931VH==DKT64?O_*#
M4/(OO_-KD"Z]]_-//_57O_5?/_9O#U;WEP\8OR15)39[?_93/QV1O0Z\_5*V
M%6:GAU%A!E8#Z?AG._IB.VZ"<$2D_\>Y;W/\9W\H@0`DCB0@D&B:)H$8M&HL
MS]"3"@"M[WSO_\"@<$@L&H_(I'+);#J?,8-!`3L8$`@((;`X"!@$!:,%:!P0
M#L-A`79-#Y""`A$8HPJ!*23P".2L6"(#>0L)$"9:A0,C`W0+``-76@@'!0T"
M+0%T=A"#7`6'#09CHR)4`0H+G08!#3F-FC8D=0IPG@N@9:,PH:]Y)Q"L"``%
MN!`)P"\*!J%7#(:'F@J+"08+"E#9VMO<W=[?X.'B12QQ#P,`V!`+60`,BPW8
M`PXB`LP)#J`(S`&VSWNJYJ%8L`A.#1'I1+"#,"Q8@T,G$(`BP>K8"41[,L'@
MTHD>!`$$XO\X"&F/`"A9.0@X,#0-P@%Z"@P1D$4"1[V0!49^-&"R9@X#AN`4
MR$(@A\V#!4X,D&7OF"H"JB"L))`%`@-FX[)JW<JUJ]>O8&4\(D%%Q$N(]6`P
MS0%`U@NK.2"DRBB"I@@$#`P>E%N%GL<1901,)#%@`-6+R32Z4*N%YM6/<?>*
M:*#VQ8NE(^S62^F8V5&?QQP$6*1204C(=440&'!@+=J*(P)@>A$YK.W;N'/K
MWLU5`+2T"&U@Q)0:==O%->+*IBLYMH.H3&$</U="@`!UA(<APOCV+7/A-(E_
MIJD`6(U%P3/?8!N^Q><11Q,P>!='@`.C<=W"<8U(TZRJO`4HX(#_!!9H(`H(
M`%/`%@\YA=9'C!GGEGM5[?,="J\PD(-;#2:@"F4B&&+"`(^1)2)BR'GGG0WS
M0-,`*..9Y0!I5F&5P%+0:(9:BY/!6-MFAR@40`&+&'#"43:<49Q-B."S"#H'
MT'?,@516:>656"JAT@+^#6"&7*`DT&`#62P%CR$)4!=(`0P021!#95(W`BX#
M"+#(2I!\J4"8#V`!AYCFZ"573`HTD(!*"2"#BS5P!&*F2PT,(,=DT)B9DP$`
M`*!*:W,P@X"AK6$EB*%F13HI!*2B0&H_ZQ20D!2#`F#``P<<X`H?<)`***J4
M3>/E&&]F*>RPQ!9KY19ZL<93)YDNF"DZ_\T^VVQ1`(1$@!JD94IM;058@1X`
M!BE[6C2O3*LM(P'<:,`B``10%"B1$$#MMB+@`8VKD!RB;:;\UION"%80<`!Z
M"#WK[[T&CX"O82R$A(X?@JCA4I$#\X0OM?!*@9ZXQG;L\<<@ARSRR"27;/+)
M**>L\LHLM^SRRS#'+//,--=L\\TXYZSSSCSW[///0`<M]-!$%VWTT4@GK?32
M3#?M]--01RWUU%17;?756&>M]=9<=^WUUV"'+?;89)=M]MEHIZWVVFRW[?;;
M<,<M]]QTUVWWW7CGK??>?/?M]]^`!R[XX(07;OCA@/%;;;W$@'7N#M02K`V^
M-!@PV,W-$A%Y$?^60RMY,)>C,,CG-+@:NI:9%I$Y$X_KG*B^XVJ1.LL-/%"+
M`W8N95Y7:?*B`P(/_$C";TG4/D-;N]NL>Q'`"^\#\@P%7\(#P/0T2Q\[5$H]
M%,83L3P3O?/\@`WAD]#]R@)@#SPVVW_5EN\T\.%\1TRD7_GI-;<_A/R<@\(_
M11-Y3R=&HP.!U"5Y2[!?$?2GA/?Q['4.K(F.3I:^3#Q`%>T;RIY"9`T8P&)(
MG4!`3%!P@'3)QET)@D8UN&06/R"C*-@K(?[B<(WFM=`W6J@=Q#08ND@@P!A;
M&-)"0H0)!2J,#EDHH2^P\!8ERN9R>(!8K29Q&2TT48HN!`E@^F$D!!3_)(LA
M.4-#@IB`=A&`!>Z*Q(\TX<4;&B(2[N+('GS#P%7\$!1!+`:`BC$'Z6VQ5M>Y
M%G'B,(66*'$/?FPA)!1@NV2Q8C6LD$.P5*/##?E&`'K1!/SB(,)<]`,9F<3"
M(A3H"02<QC+0T&1LZ(A`5<)1DE\<S19`P<-#8,\E6$C)"SRT@-/4DC!7,$9&
M_L4(.H"0*E4\A)\0\DE,IJ"$..2D?_[81?2(,2Y#Z9(Q7<6JMF#!F1^112-&
M:+(*AM,0VU.)P&:4I@&D"0YS"$8.S#"3VK0E4L#+0@,8<(QSO-.6\7B`J[`G
M,17,PXNUR\&GHB>OA,IK)"^1')E0Q<]PLN(!_R+":$XT\P]5.%`,+J&5+7W#
M@`;!!Z/Z(A$SKE$/\)#A`0&]W`/R40#LW9.1!3``/6H:$N#UXQ4.H,ZZ2"#"
MI6!CH<`+"1\$L`!Z\($U=9SH/EMZT3<Z`*&)K$L^TF2GI"+*J+:TH#W[,`!&
M6NYZ.>!#3/I$`@(XM`9Y68":L,$)U4!T1G!=PUS!JL`%J*(4MHI#"T1H%0M"
M-7F$M8-:TY2%FE:4*'=%!T%W^@"2T(I$)U!G1,VG3WX&%@]DR0*F5+H.;-04
M%`XPR`/B*J>[/"2I5C%$5#)#T\F:(R0=E8MH+6E+@LP*#@JD9U9%EK[K-*0&
M$0%/HD82/KD2)4T;`O]06!%I%/(QUZ:V`TP?JB$#Z%*7(:^5G@*!9TOB294I
M+HU>2U'@@-2&Q(';<Z`#C1BB[-Y#>D\-YW3;@AT2M&^J_!W!)>I2IO:*"GAP
M$%4GU->H\*95I),!1E3UB=[I>O=_F;D(]N3WU?AN.*L.Q+`+\"N].AIQ>_);
MBGM,JMZVH/,$*6:P?E5<WEG9:378$\!#!HQ<PN3X(?QK7_JJU2CE.I#';!UO
M9<GK8LZBR@8V-@P)G*N%"Y^#O!]I$(JSBE3IM?<`L>LQ15$EX2Q\.214#HF'
MU:(*^WF7K24SIW^/U`?:=*(\V-MHI-3Z`D&%6+SBQ/-+>7%/F,J`?_\K1D+_
M]1M.R_P(&0RH\'PK3(+69'>^#_'NI%,0:8%]EW_VD^\M42#D]![PU(C$SDS:
M=+D(*FP!B\9P^^IHD4BO]\\/_M&:OPN078L8URA`=(F3=V(8!P]YEI&@HWLL
M/U?K5]2CJ5T^D/V66>^.VF(5<YIJT5)'PU?"=!ZQ">H,L>%]@472AF)0]TSB
M<:^7V<-5M/0LW5\QV\_:(<VNGA>QZQ[;C\^LBO.H3RW7<:G$#]B35*2M`&$,
M?;BZ6A`-M+4KPEN&;E:Y[F>[`*V0RJH`#762-/;D^FY&O*2R#O12@J238QW-
MJ@VM>;!E]SOP#->#'JYF@(35<?)QR35Y-64Q=(4=_QG<H7H$(%=@J`G:;E)K
M.-L#]C6('Q[LIIN8)ELF1G934/`Y4S?H$FS,2P<6\CUM701&%W.]SOY=_2V\
MX^-RH,[K@@T%\J$8'D]!TEE4=L*PB58Q1V08F%+1K`\O>/QC35!C)V1ZS+T&
M\NBYPD7:[R1#N>%Q()F<;=X:@F2*#XDB:&%HM6IY^9GJ_\9H^%S]/A()E*MM
M9:M<J]L(Z14<7!>$EG]W+/(6M.9&MIY%/V'H^WIO6G3/L2L\&R37V@]:!:LM
MC`.PX6J\-.:-:CA[6Q0L@K<#]\I--\4Y:IH\0W=OZ2V8219F[_3I-KM/RP.V
M=ELPJ]?%QNK)NSV\<Q!I2/\HN/.Z9WC>QVCQX!(CD3H%V'^1(!?C5T<*R`_#
M=G_6E'O\HC[\-!.&D#XPXED46!OF)QSSU%_KLA1@EEIRD6D>QP!587@G57MI
M-7S^]0[S<%07B%(MD";7,GK[H6&-Q7&E)S"<(C*:(@`2`1A,U5.K!0<`@#OX
MX%MSP'/M)5W!0(2'P1,+@`-+Z!O/$0E$B![5U$7X\!<BH%-^)0K!T$AYQD+1
MDQ<#(1K-`Q4X4$UR,7V74!M/R`S5)%?C8P==5`P")!>_X2&?4"\.D!==*(>D
M1B8Z5R1=*`A/F'XQ@0R?(24D8`G4$Q*S4@MDE2"B0@!?$`#/$3M-%0O5<H6R
MTHC_9`AK"F8"O=1%54@BS[!/@F1*G$@175A6+2$(G-@(]L"*L5,,9,!40]$4
M?S=)=Y&$$($+M6B)(`&'.0",A7`(7-)+<1!I;^*)8Q"*E6B-A<&)OJ@:_04\
M;%A-925",%!!7S`1XB@HZ^"&QS:-L3,%A.44@[@'3\@NPEB+(Y")K=$"=YB(
M>&$G=V:.IB!">/B$R5@4"D`%79`(-O$25W4(:;`V4A@@!W`*C*0#H,!]"X1`
M0;"1B`,.]'4EM!:2,E`)!J(3]5$Z&,611%"2/X!Q\V.23C"25@*3-$D8I!,@
M[?("0T4#\90$K#A#/0`5[)B33P"'Q%,E0XF43OF44!F5_U(YE519E5;I-3UY
M5CUP2#.P!CN9`E%T%Q59!`/0D%M1ED?I%8%0`@$7`ZQ1;BW3+FE90(]$-D$T
M#EPY`T,A3$8@EP:R>?$3')LT$`+%`PK47D@``S4U6UFQF(X3%XBI+T<7`\ZV
M"DDPF+B!DP:%%2*6#;.S!SACD]U0F2J0C6/I`[R@F;@!F#)@)())`Y+2`PHD
M+T?@FO7RE>!`)%]!(G%!F[PYF2I0F6IH!#4U(*HY$!LQ7$_PFU,8FA/$#:3I
M<)CI`[:I=@-B3G#X$I%"$3,E&-Z4/N'"#C=VA0[))HS)$`Q0*,)!A#3$!:]P
M#2_"BR9`#V69()'0G3GE3.58%O^\&"7Y$`5$J`#))Y_VT9[1:`*"<1E&8A!8
M\"(&6ANP$)$$2I_B^3D7Z4PF@`79Y58P-0Q46#L3U3X7:A#FR4B^(U=SMY^^
M4U;LJ2F2,HTB$E3.-*)M19X+.H4BE'P&*A-7J)V24Y:HL"X)XBKL24-,Q6]$
MR'8A,HV@@*+&-@K_Z1+E`0=P:)[%A`DF:@TK<1<&<`F&`:+[@)]PXJ`+"CS=
M0@4LQDEH8`M<L@S5007SP0)I5T)L``I>`!*-\!LF,`<E]5Y$^!+K\H@A%*`/
M@!7%L!!5R@!MEB36L1H(0#QE62BT!*,.:22IU0IM4)\"J5W7,'U/4J%/UB;V
M6%0000G_$TFC^RBFU+,^@@"JMR%G0_9/7M=;OU(/^E1WZ,5$E290KD=P'F44
M67!!B&0/;7:K8N9`UE=/B#0:2LJI_00'2V4-J((-FR572N)^K\5/?B69<\)/
M=S>LTLJ>!:A=[N1QJT45'O<_+.AAY8I;?S5P$92L694F3Y$KU(I7"M06[1IV
MHJ8*_U2`FQ6KF#<*A0&!O-4BVP=7Z!H[*@%/3S=BS$I]_N1QZ:.K]^<9A2FL
MLP)#!HMJK8">MF2(*L$/[%5W]$"P"QB#DJ4*=U=3^Q$5G18,I":#6S=3UI``
M\OI@GE)9+4*"X:2K"A2SW,>>P@JP^)JQ[Y"PXMI?WF1+GF&L_PZ$@X6E53>K
MKU)K<W4!!K"UM*MY2^C7?M-E/S.A`&7`3TK76B.0D8RV/8S4`*LQ$S?H/RC5
M&&0[5>TC=SO7=AXY737`LG,+M[9$I>,S$7+G"HPT>&XK.6=0EB0&#6-;MF01
M/+^U?[RVKB?`2+)">MCE.Q'T>$K::0,#N&WQ?>*7N8+RM1%T0:(K4E\+,#.5
M+T%V`H$W5"QH%B1&?.+68Y@[N>E#.J`F"]M3#(-`=6)64NF`<G!F%;839I1`
M`+;6&O?Q.5('";@`/6?H>V!;H#5@4IZ+#?RS?:$28+U[4F,80[$7MZM+NCWV
M/H\[5?-W0.W+3Q]%>'5A4KN+>?J3=?_QV[7G:&I8NVG\U2]GJP(#W&->,E,P
M)%W_$\"I<[?8@V^Q2YFWQ((3QX`LUP(PQ2^%(6UA9B3LM\"VTR\GQ2]J9FP9
M1[G^=FS54L&O*69U-"MY0'/N@5XDS*^;>T`3U[II.SZ&$,&@YW4B1G01%,%#
M=BZB^;NH5@8^5;D2Y@K2,FIZ)CH_U#V,-+<V!VR>N%2"<&;9"[SF`<'2\SY\
M@"F-0U^DQ,44][['MV8,/%9J@0,AG#K'IT#Z4\2+@[7[U\;\>VLUY\`SW!C5
MPVBBR4BCY,5:P+@\L5IHI1KM4\*OB619$,&1(#FIZ[U^1&--QA#MQ2[8PP!X
M51BK(5<*Q@?_6Q!^,Q'(.]R;E*NN)GQJF*L:ZL>W+0S)HH/`"_92&2@+KZP%
M-OQ\D(?)**7#O,P'?LM;06AS(F9EDI6<O+7+,Y<"2+R^M")_[>/)3[+,(V`2
MM7,Y7Z!?2B6L7H=K,ZAVC'2>]E9XYD'+WPMXM_3,)5?.*+!JC(!=N7QJ[-O(
MTU,9IZP:TX5E.G9TSCRK^[?/O/RJ7NN_W9<7N'NVZ:*^HKE]&X6D>W`2U46V
MV=9M"0`'\P%F#J13YB"WO"573`M3]WG"Z_!7],$32_QGCY`)%"U!"<!(/9Q(
M%931TV,HRV)X_;B#(<4J'H;3)/$.C"1=,[$`>$A9IS,7"H'2B\!(_P>0*3!5
M#;$CTW+U4I&"<2<=#/0AS+("(3VMQ?-0J#9=NYWP&-M:U!W[TU+-:%4'<?"6
M!V2UTU:AT,3<+K(\#4LH.:M5!N?0U8-TQ0_7%H]`/>@Q$T<Y4P504V^\CTB=
M:NTH?:GUU&S-UH9]`R'<`MM*L&O[L#5]>MB`#Y;5T--U6E*!%?IS3VL]`AOM
MR+\KVK:1E0M"&R7TDZKA+BZ1!U'T"N7!#$%4+7;V3)A`!]SD+BQ`";I(''"4
M++M=VV&4!P612ZOP4R]0%.1)<2D4W<GR`J84#0(SW;.]"++11L7-CB90"9B4
MW(RPW"B`#!O4DSD5<%/4DV&DA--M$1ND!?^I<)$#4P(_>4W!&1FE=!IJ1$3W
MS0C7@`?KXDW7/4":8"VR[=P*8QGH<4?U+0<XY-ZLP([(1$"',((9+M_VC4>_
MS0@9WMOR#17N,D139$6GU(C?/8::\"/6`"Z"$44<SDSN,MO7PBH+2163Y)'4
M8R324=]F`=V(-`7"=*@R\=N]#1\&M7*"H-T.[@?R_=TLRGW=(@P3<>4M-%0`
ML$S18-L$'CI;\%XO\-ZVH-YNXVGOZS;1Z38+Z)+'"<W*R0-Q?I6XT2W2^39O
MWC:SLBPI,.=M+01_'F9XGALZ[C:)/C>1@#_N[0/)C9LST.B'7NF6?NF8GNF:
M;ANZ22RT*3.)O>G_HJX5$^&85P)[4B&&7X$_A"OH/U!QISGJLLX]K3J7!=(^
M:QD6:3H9>)P$<*N5LQ[LI4,,R")8D5%"XX+LI3LOL-,N&\,*K1//$`X[6R`Y
M.XY-Q'Y,F?.9(3+MW!V\G^F7LL,6BV,ZC;XO!.0YR*XLA1UPZ(X>F#O5P5/"
ML[1%Y0()74TNV3SMF2CIPO[O2Y$&2^4AU$$%2Q@2!G^`D>9"V,-5:!`0HC$/
MKA"<_H17]+IHA'B&K[!:GT*?_7<,@D(%F%5?./M?',(0P&`\X;,4#5#5#J^C
MP(,#\_&H;,4F=9(%+^]1"Q\9[M`'&Z*"#>`17L`CZ_.\=K*E5HM7C*1%___>
M]#$PO36U(4-28G\LP_J%U=I[`Q+&#-!3&[,R4(O-/ZV11.RUJ/6@9<!`QR\%
M(Z8V4Y*"S7;'<3U&GGP0MI06=J?&/Z+Q$<8V&JCE'D>R];+L](0/V&+%9T2(
M^%F0KS=L/X'7S=`';H.O,+8RP:T\#S/"?28AH(9L;^D%P);_OG'OUMNS6JC@
MG2U7<N2;]\=&/5S0RB/U^B[\L(5?^])\^%;\PZN?P[I<"%NJ`FDGK*19)X,=
M]GX$/'PI(TG1^:5F#B^%L7Q[VJG_771\`H8F^G>_^GF<O+S6M",0_!Y5<[;_
M[U#?/@E`?B&B7V!O]W=11M;T^PKQ$$O!]>(OD_^A_S\SL>M&UU?T"0*/`$'"
M0SH(E#Q%>1Y/0(HD!,@O&3R`#M46O=L`-S.1D"Z;$CCB^1R.P0H"M4FI"<BB
M`1D\#+><P>&SH=/J-;OM?L/C\CF];K_C\_H]O^__`P:VX3`0\"P0",TH/#`L
M4#$Z:CDH#!Q:/BP4,/3@-`@(!`PPCM@0,"0$E%ZFQ3089!8U%BC:+!RH<:H.
M`3@L1!+\)#0`+,RL/#0P/A(&6V5N]@PHGG8V$A0XB.`>1OLD4%+9@%<2TN;$
M.`@43.>0I*]#G*:NQC+B"N;K[_/W^_\##"AP(*`"2T@8O/,)5!@(!12H`7#0
M#3N'SMH8$(=F@(LB-CS_'D1"HLA%BX**:`1$X`R;E6DDLIE(<";-FC9OXLRI
M<V<<`RI((,!UH*0@`@X*'+,3=`$#GDZ?0HTJ=2K5JE;W$%`08.N,`D1/2L)S
MH,N6JV;/HDVK=BW;MF[?PHTK=R[=NG;OXLVK=R_?OG[_`@XL>##APH8/(TZL
M>#'CQHX?0XXL>3+ERI8O8\ZL>3/GSIX_@PXM>C3ITJ9/HTZM>C7KUJY?PXXM
M>S;MVK9OX\ZM>S?OWKY_`P\N?#CQXL:/(T^N?#GSYLZ?0X\N?3KUZM:O8\^N
M?3OW[MZ_@P\O?CSY\N;/HT^O?CW[]N[?PX\O?S[]^O;OX\^O?S___O[_`QB@
M_X`#$EB@@0<BF*"""S+8H(,/0ABAA!-26*&%%V*8H88;<MBAAQ^"&**((Y)8
MHHDGHIBBBBNRV**++\(8(V$%&,!5`&7%.$`J7"60DHR2\?!$,C\"(8T"#N##
M1E)$%A8D#2W\^,`0`VC#4AH&E,)DDS40\,`4!X!"P``(;,&4CR-*><8R#B&`
M`)(0P**."P<H(``^9FJI%P\,(,!``\YP$HP8$`2*8IH[2`D!)24X0$,I..CX
M0#"%YHF7D[`PX`(L,^`SP%=H#O',"4%5XR@)C```"RZ>5IJ7DQ`T\`!$5"+Y
MJ8F'0H!`)E\@T,4)3B31"0"VMCK7JR9`!,&:)`"0Y/^MH7*RA0!-B52#LJ$&
MTVRQ=_'@10R%D-!EDMK(!&J/1^+3"`"Q4L$``T-YDH`!P9"[+5TTVFAE"6@8
MD&R).MK8HPT&+-!L/(8XDX``"BS1K[U]#2#&H&\`8*/%%V.<L<8;<]RQQQ^#
M'++((W?L[&,'D)RRRBNSW+++&YL'R[QQK`2`S3?CG+/.._/<L\\_`QVTT$,3
M7;31.9?;6`%',]VTTT]#';7/YD6<],-78YVUUEMSW;777X,=MMACDUVVV6>C
MG;;::[/=MMMOPQVWW'/37;?==^.=M]Y[\]VWWW\#'KC@@Q->N.&'(YZXXHLS
MWKCCCT,>N>234UZYY9=CGKG_YIMSWKGGGX,>NNBCDUZZZ:>CGKKJJ[/>NNNO
MPQZ[[+/37KOMM^.>N^Z[MU8``@(8(P`"Q*:H(RAM(J"O&F>B[B0.C48Y!"S^
M+D^]ZJ_BNCSQ'^+*2:<PG9JE0P>Q*KKS0\8@Z31;4/KL&;IZJP`X*L09CU:_
MD-#^YWO"[XP)FI(`3R?"%0].L*MJE2(&8W"!`$'GI`)(:0LQJ`2.5$1`+ZV@
M``?0AJFX(`-&3&QTQ]H5H63`//>=2E8.>04"@W4]:\7J&#SPE\,,-24IN,!/
M/ZC!F!Z`#TU9SW.Z8@``&%&)D81*45`R$1AD,(QX*,H!!HB5"P3@`%$8)04(
MH$*]_T"W-)RI@7K:8F+.4I(JCHB"6:8(P`'$,<;4T6(`)F,#F$!AQSOB,8]Z
MW",?^^C'/P(RD((<)"$+F<>?1.9WAEPD(QOIR$="DH_FB4$:>;>MBE@RDYK<
M)"<[Z<E/@C*4HAPE*4MIRE.B,I6J7"4K6^G*5\(REK*<)2W%MKV`W!(-N>S#
M]JPVAP'X2$QIV65+!E*^-0CSER?T`S';T$PZ//,.P.2'+_%P3%.\`1O%#-=;
MY"@`EOA.8'H@`)8"T*9@%"`4.)F&^-PPBG;FXYT4@1X>>J&O!82P*O*49IT&
M0K`VX',.]M3'/JW9ST"D<TE8*><Y;V"&?60C$/_DUZ_88/\`A2%R)/U,:%S<
M=!&%;J2:+_E5&8*QE9P``)Z#4.D-`)'2>"[AFV]Y:3U9R@;EZ0&G<>!($G3:
M!YKF`:B`..D?<$""DI;`IU1A2467-P(=1605(!V(4ND0@"Z(8ZI`J2H:C$J#
M&1#U)D*E&$N]4%2;ZB%Y/9TI6LDZAT0`PJQ*.8-,]3%6.]RU#V']:45S4->T
MR+6I+[$I3?=*$+CJ=0#*V($-`M`O7)`#%S3Z73"&,5(D<N,8!L"2&,9T51]8
M`DLDD!?^UGB+:66%`3(,@`+$L"X#J/:EB1!G&GQW5:FV]AD!\,%F!9!/E"$`
M(@]!0`!4BQ#B+J"=.Y)84WAU53;_OK9/%8QL"7R""H=HY0N.%5\!&J"P!ZA@
MN*"`P`%\HH(Q"8``B5A)**C@V(TX=@%;L"TBQK0`-W$$N>T$KG`50%SCLNFV
M:!#O"'J;$:8$8++R"(I]W30,ZU;0OKH%9W9AFP`%@&L<E,"%;Z5[5,[6UB?I
M'6YQCU&QX%*!IN5MTTBV.UJ")8N^[9SLB/U;8GG<EPKE70&,=W",%:L@*^84
M`14B%@!BW/178.`P:&N$9/JBT['),G`:E@NGYGK6&`>([G5-88R(Q6.S$N;!
M;H%PX0PS"\.[#8I#-'$#J:;!$%?MR%;<_%H^:457`BARG5U`X"P#8!JJ%9.3
MN;J&KES1_PH[6-5UZ[J`4ST:JEWMA`*2==(#;*%+^%I!@26XX/R%$``,H,)B
MJ>20I_[*M]AX*0)\.6KRCB"=7_C5KS`MCR6B@`1(ONH7H/=J,*4A@30XE0_H
ME`0Q).#1:*BK;U>@[)->E+S!WB(.7'#5(A0Q@.=EP&:74&F@I$2M4^2"#XA[
M@U&S3\?MA-ZN(^UK=:?AVLW*=`MH6M@9B!JJS4[V8(<=[V-`"0'Y9#:R'VUK
M3:-!V0IX-*]-C5@';.&EV>8"_3Q-@)]PFU#P3CBDK>#NHY8B(Q<'M17PG:S[
M6B&]IQ##$3>89)M].ZG*TG&C"I:K&3Q"V@?'];ZD#01BDS=9^_]6=F,ATB7W
MIK@4?76!P/M=\K7>.]A40'EZ'>*`8*@:*2K/>-6S85)FU(C3;SX5S>]P#!:D
M(G]J>K1,1<V5.3+K`21I[!&TLA4Q>>IW*[BB>T.Q%2O15)T_EX<<4WV&=4%Q
M#0IC5BG$I,#!+XPK)0G&`78-<+&/'0V?8&H`(Z[LMK>3V3Z(.C@JR80S&./I
MROHQ]"`XL2X%(Z.*BO,-4D_3Q6<>FY7W`5%/@/NQ$C7R=[<WG($*>J<+5O6_
M,JSHQR[\`%S$[5O)[+##WM419)>\C2I]W[D"@-^+3_IL5/Y(KJYH57C_Z=EW
M.5%%*P.N)'GN:WW_2;.5^C[AX_DEV;S_#7XEW]I#73L9A3R\B8DI7?_YF-,%
MW^C!F0W(FBE4%->=0?NE5P2*`5$!T\6-`$W1GU:]05($@"_0P`2.0-O)U2`D
MWTD)0(0ES^VYBR7(G@T$WN59`2X8'N,M3!NH`N,MVN"E6@6A07D-@$SU7LKQ
MX$:`D+^E4Q'%%`,&&UTYH>HEP`LNVP2"U3$(GE<-X0EJQ9:E@=P-V/"<5&$]
MRGYE!!%>W@[F7@*60`417P(:7Q3*X`'^F[\Q'Q0Z'Q`RRPF2GSGU6Q;^RA2.
MFA\V5AEV%1\6X:F0B4G)G@J:V`D0U4N!H1MX514"04KXCISM@`BN(!N,0D,,
MWA(R3`"J@7?=_P@Q'!X=#IYA19W,M>(>3AH3'($5,EXEJA,&MN`&*MTRQ<&2
M"$$2_$33R13"5<$:5"+=*8NR88/\C!WJL=&K%>,1"AX,_,0-OMD`9)SB@>%+
M'4`U^MO"A<M!$(!9H>&PL4#2O81#T!I")$"@G=X:RIPK%E\`+4E=C2)1'=EH
M/=L0)H51!%$#G)W&/=WM;:/XC.-:%>$YPB-1@:,\+(TA#F26'-_U^1L:).(=
MDF)#:E.X+-$6).04?($3YJ.SM107/*,X)(!""A4Q>B0-$N"/06-+6H%9\1M1
M[5@VZF'<J8%,X:1`CN$7$)%&3H0/0)`2MJ-&3&00-MNB'&%?L>$<LO_A1.X5
M&)Q!CT"<KE41+9)71EPEK%C;,3"CQ)5"3RJ%1B@60F3*-$S=C2A+"BC`-_`A
M"Q`%BV5#*$!$I5V8*>*")BB6:N7<.)A5`YR7W.T>#^""=XV6%T#081*=KA6,
M=!6F#RE*.]8E:^D2Q,$6]+$8&)#:8W:9KG%$I(&A`"Q$&B&F924<6YZF6;'8
M^+D9$PB7LK'8%S0`+HQBM$'00>16E8$7FW$;F+PE:L**9^*(4<C+H&TF&#8`
M<:+!;%:F<*&">D&<PFB"<*YFE9D5Q%E)<E+!;-J":FZ!93UG&AQ)<)7;8)(:
M0!Z192F6;5K;7K)#`_AE9P*`A]E`>;YEKJ#_)Q-TBGQ>FW[2IGO.)##M&7G)
M2M,)YVA)2AH@Y@0UW6\N3#&PPYZ-I^:%YJQ1`6F"@FF&)Q_V6G=.#&IJ)V<"
M:!":U>X=P*"AIG<"Q16-8N5Q1+(@YH`.H8XU0(P"Q4_@I0)XUR8D``$X:#[%
MP1=IA#@:0!N%2T:,5H*-1`75C#N&B\T$`SDAJ27TB,BE@C/(T<Q\A,UXA<U@
M&V^UT;P0*;9]Z;#PVT8<:0&4Q9%&3+;@`Y7ZB+P00#O6S)-^P9H"8:K@P\U8
M0<684ZM)J9?J4D9\4<V<J7IE:;"55YQ*Z4B45S`4@9^!*;@98YDY1()ID)F.
MA)Y6V;S8Z:#:3)X>_P";ZM*CRH.;OL/A09]$<.JA$NI($.H;R8.H#@NJ)BE'
MB*H+R*D:I`*OVFJ>*BFG;JDSU"GT02J71DRIZN&OUNJMCJH:?42D/JND4JL5
M!(62(@1;?H&3WDR15BI2E`52&(1D"6&2(FE7'2FSC.IN;46;P"KX=%6X:.FL
MXL+-W*DIQ*H0_JB9YFL0(NNVCFNEFM.Y"FR4#HMV7:F.G8&X>H8<744"9)20
M`L)?Y<&8((AA487$\DM=:*QM&)I.;((Q;`4O[H%B4>P<0%#5'4A#7L7(<H7)
MJH7+[L=*R.P>$&E.)<B_FH7-V@7/UE+0"BUS+(U*Y.1H19,;U"D=1(P=_/]H
M'%2,I'KJ/RPM'$0MJ9JJ7D!L[M""!]H!>MT4$?T!V+Y58T*MV'X@FTX!1'R"
MUXZMWJ4M.(P"K`A>7CQ>[GQL4-F4Q>9!G[95'_#M&C07D,[`-`%$7J7!X*+,
M%]PL0<#='B1?Y4SI1:`$-GE%2)ZJ&OSD3D%I&F#;WAI:PBJ)`3J$&9FEIU`!
M\8@N0A!`X%XN`CYE271NY8;+-=6J+I6DK-Z52\"NZLF#''0N$7P$ZOYN\+YN
M[3J#Z`I50D3$%\@@Y79NY$Z.S(2@"TCLN@P+`KR"KDCL`CS;<:8$:S'%U?7"
M$67?:"4/D@5A\H"")8Q`(F#AL#3`GY#77^)8,63_Q`[";SJIT[J84^NQ[[U>
M$9_``CT>F6+NUBM\@7R5@96,0GT:'9D93'L=5'VNBP1A&A&E4YV<8%!,(4<`
MSU4I6S>F5#MY\*@9@@Q,L"CT4R\\6D!U5?K.5P`[5''52:\P@/D]<'"=&@<G
M`OZ.PJ"-21&9;?+D)U*\U@JD[QE([^2`X4FYV1B2HS<6D<T`V`X(G0JHH>Q%
M\9)@XVCI8E2.'DB6*K^X5A@_7222HP^\&AA4T:J$HD-E9<5`XJ"H[ZF4A0(/
MGNK1E%DYUA#:3')9P:R@07,1H3=^,>;9@"$S,3)F7B_(2RGN@!BT,938B79]
MG@HP(ZQ<X*QL5C.N@@%\_U\2%<,7S#$/<,%75B3F+-\Q`*GME<(T#C*^6N39
M/=518&R<C<62`!LHB_&Q*<OR2"P:GU0DQK)$5!1`QN,>4TE9"`L;XR$6O(\J
M&O,:8B^A?BR-6-ZP]?)=:7,CLR%0A6!4#5@RSR(;`MM#Y<H3)(6.Z%W@B7*E
MCH1\.C,8R<,NK_+EM#)Y76'FR;)ECD0M,\NSM191+.Y>C:18_O*Y:5!ME0,Q
M][,_V\PD-MM?)3,B+:CS/D!96.Q&[X"R550UBUJ7-I?S:FQ^EN//)70[H30X
M\W&6')E"C;2L4K08U%4D/II'>YSJ/401H/$E!_1'A*`89+2.17032\X^0\\8
MQO_RY8%#1U00/G8*4Z+!4B\)!&4+&IO;,I.FC]B<0M_<2Z_5N^0/UG%>KIB5
M#RR6M)66Q<:<`J2+(].4%'U!&TFFM!G6`Z;T"6#U&NJU2U<S>7G%4:0!74,L
M61.*6;/ANKXU]9&;+Z-UBD5?98W`6N."5?N;X5(.VB4"(@"/(J5"IIS"(Z#=
MM8P7&BA,2BX)FP7;?8&"E:C9D5BEP"670:@62@;1D077NU`);:]#Y8E"<=FV
M*/CHNFY"&J$="Q!7/F:#G\P7)127_:(LQQ;>?`&/F`BW@0*/CB7#GW1V2?1V
MG[RE]]:I1\=V5_9:FS``P\2`==>7<*<4@3;`1,3`=CN1!"H8]VU;`2JDZ70'
M&7G/Y&X/Q16)20.H0T9AKUHU-V)^]FN7=LQMCD?8;DM83?#FRAI(^%=XA>%Z
MA*V4<410P1)TN`-23..^A%GZP*<<KQSPKJQF$Z\NTX8'$XSSDKY8N(]MI`/:
MBCLN03*9!(AWE3ADN.>:^.M(A-OB;%9@1]X.[1U`T!'M@YQ<1^O2;RJ%```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
